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“Woke up lost 
In a world I didn’t know  
I shook it off and 
I’m trying to make a go”
[...]
“All things being equal  
I’d rather not forget 
The things I’ve seen 
And the people that I’ve met”
Eels, parallels
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Alzheimer's disease 
Worldwide an estimated 47 million people suffer from dementia, with about half of the cases 
being caused by Alzheimer's disease (AD)1. Advancing age is the most important risk factor for 
AD with an incidence of 0.4% per year in people aged 60 up to 64 years and rising to 10.5% per 
year in the population over 90 years of age1. 
Alzheimer's disease is a progressive neurodegenerative disorder causing cognitive decline 
leading to loss of independence, institutionalization and eventually death. Like any type 
of dementia it is characterized by memory loss and by cognitive dysfunction affecting other 
domains, such as planning, inhibition, language, or wayfinding. In the brain the classic 
pathologies in AD are progressive atrophy, amyloid plaques and neurofibrillary tangles. In 
addition, vascular pathology, an altered membrane composition, synaptic dysfunction and 
a loss of enzymes related to energy metabolism have been observed2-4. A wealth of modern 
imaging techniques are now able to demonstrate and follow alterations in vivo, such as glucose 
hypometabolism, reduced task-related activity, reduced resting default-mode activity, loss of 
white matter tracts, and hypoperfusion5,6. Although ultimately the entire brain is affected by AD, 
many pathologies develop in distinct regional patterns with anatomical  preferences (Figure 1)7. 
Figure 2 shows several of those important brain structures, that are known for their involvement 
in AD. The hippocampus (HC) and adjacent cortices (medial temporal lobe) show characteristic 
atrophy and tangles of neurofibrillary tau. The retrosplenial cortex (RSC), part of the posterior 
cingulate cortex, is another region affected by atrophy and tau tangles early in the course of the 
disease, but this region also displays marked glucose hypometabolism. Finally, the anterior part 
of the cingulate cortex, anatomically and functionally part of the limbic system and the default 
mode network, is most likely affected by degeneration of connecting pathways from the medial 
temporal lobe and RSC.  
Despite over a century of research, no cure for AD is currently available. Drugs have so far 
yielded disappointing results, with very modest efficacy and many side effects. In the past 
decades, several modifiable risk factors have been identified that open a window of opportunity 
to prevent or slow cognitive decline8. These mainly consist of lifestyle habits such as diet and 
physical, cognitive and social activity. There is strong epidemiological evidence that these factors 
can reduce the risk of cognitive decline and of developing dementia and/or AD8, and may be 
related to the recently reported reduced incidence of dementia in high-income countries9,10. This 
indicates that these lifestyle factors may have a causative or protective role in AD and raises 
the question whether changing lifestyle, or lifestyle components, can slow, revert or prevent 
cognitive decline. In this thesis, I will focus on the role of diet, and more specifically nutritional 
supplements, in AD. 
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Figure 1 
Anatomical imaging information. Hypothetical graph of appearance of imaging biomarker abnormalities in 
different brain regions. Anatomical variation exists in the time courses of biomarker abnormalities within 
imaging modes. For example, in FDG-PET, one would expect abnormalities to appear in the following order: 
precuneus/posterior cingulate, lateral temporal, and frontal lobe much later. Similarly, in structural MRI, one 
would expect abnormalities to appear in the following order: medial temporal, lateral temporal, and frontal 
lobe later. FGD-PET, fl uorodeoxyglucose positron emission tomography; MRI, magnetic resonance imaging. 
Reprinted with permission from Jack et al. (2010)7; fi gure caption adapted for clarity.
Figure 2 
The main brain structures involved in Alzheimer’s disease. ACC, anterior cingulate cortex; RSC, retrosplenial 
cortex; HC, hippocampus.
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Diet as a modifiable risk factor
Diet can have a major impact on health and disease, in that it can both prevent and cause 
disease, but also improve or worsen recovery from (treatment of) disease. This also gives us 
opportunities for prevention, risk reduction and possibly even treatment of disease, including 
diseases that affect brain health and cognition. 
Epidemiological data are in favor of the beneficial effects of diet or of specific nutrients in AD11. 
Adhering to certain diets (e.g. Mediterranean diet) or having a balanced diet in general (preventing 
obesity) can reduce the risk of dementia and/or AD. Regarding specific food components, one 
example is the intake of products high in omega-3 fatty acids (e.g. oily fish, walnuts) that lowers 
the incidence of dementia up to 60%12. Conversely, many nutrient levels are low or even deficient in 
patients with AD compared with the general population13. One can make a distinction between the 
effects of macronutrients (e.g. carbohydrates, proteins, and fats) and micronutrients (e.g. vitamins 
and minerals) on brain disease14,15. Macronutrients have their effects on brain health mainly through 
weight, muscle mass, blood pressure, cholesterol levels, and insulin functioning. For instance, 
obesity at midlife increases the relative risk of dementia by 42% compared with a normal body mass 
index16. However, micronutrients also have direct and specific influences on the brain. For instance, 
vitamins C and E, both antioxidants, can reduce oxidative stress and omega-3 fatty acids, such 
as docosahexaenoic acid (DHA), affect inflammatory markers and membrane fluidity14,15. Figure 3 
shows several commonly investigated nutrients and the pathways through which they may impact on 
brain health and cognition. Suboptimal nutrient intake can have adverse effect on cognition and raise 
the risk of dementia. On the other side, heightened intake may have protective or enhancing effects 
on cognition. The beneficial effects of various nutrients on brain function and cognition are further 
explored in this research. The main focus will be on nutrients that are relevant to membrane function. 
Because the neural membrane is mainly composed of phospholipids, influencing phospholipid 
metabolism is a promising approach if membrane function is the process we aim to affect.  
Brain phospholipid metabolism as a target for intervention
The brain is an organ with a very high lipid content compared with other organs. Moreover, a vast 
diversity exists in lipid species, which is pivotal in the various specialized membranes that exist 
in the nervous system17. The neural membrane is mainly composed of phospholipids, of which 
phosphatidylethanolamine (PE) and phosphatidylcholine (PC) are the most abundant17,18. The 
distribution and metabolism of these phospholipid species depend on membrane functionality 
and cell type. For instance, at synaptic sites the membrane is enriched with DHA-containing PE17. 
In general, neurons are also more active than glia cells in metabolizing glycerophospholipids17, 
indicating a larger dependence on phospholipid metabolism. This is especially clear at the 
synapse, which is a site with high membrane turnover, e.g. for the recycling of synaptic vesicles. 
Synaptic functioning is therefore considered to be dependent on membrane phospholipid 
metabolism. Synaptic dysfunction is a major contributing factor to cognitive impairment in AD19, 
and altered phospholipid metabolism is thought to be imperative to this deficit18,20.
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Figure 3 
Overview of nutrients and the ways they may affect cognition. The research in this thesis mainly concerns 
nutrients that are relevant for membrane function (delineated in yellow).
The formation of PE and PC, which represent approximately 30% and 47% of neuronal membrane 
phospholipids17, is mainly controlled by the uptake of nutrients, consisting of phospholipid 
precursors and cofactors that infl uence precursor uptake and metabolism, from the circulation. 
This phospholipid synthesis is described by the Kennedy cycle21. Because the enzymes in this 
pathway are unsaturated under normal conditions and have low affi nity for their substrates, raising 
circulating levels of those substrates can increase the formation of PE and PC. Furthermore, 
increasing the availability of all precursors (i.e. uridine monophosphate (UMP), DHA, and choline) 
has a synergistic effect on phospholipid formation and on dendritic spine density in animal 
models22. Circulating levels of most of these rate-limiting phospholipid precursors and of the 
cofactors in the phospholipid synthesis pathway have been shown to be decreased in patients 
with AD13,23, thereby providing a target for intervention. Furthermore, neuronal PE content in end-
stage AD is lower than in brains obtained from people without neurodegenerative disease18. 
This suggests that low circulating levels of phospholipid precursors impact on phospholipid 
membrane composition and that these membrane alterations may be specifi c for AD. 
Nutritional interventions that contain phospholipid precursors and co-factors for phospholipid 
synthesis are expected to impact on phospholipid metabolism in the brain, especially in subjects 
with low baseline circulating levels. Figure 4 shows the Kennedy pathway of phospholipid 
synthesis, including the nutrients that are known to impact on the pathway and that are obtained 
from the circulation. Unfortunately, it is impossible to assess the composition of the neuronal 
membrane by life, but phosphocholine, phosphoethanolamine, glycerophosphocholine and 
glycerophosphoethanolamine can be assessed in vivo by phosphorus magnetic resonance 
spectroscopy (MRS). In the next section, a brief description of this technique will be given.
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Figure 4 
Kennedy pathway of phospholipid synthesis and its precursors and co-factors. CDP, cytidine diphosphate; 
CTP, cytidine triphosphate; DAG, diacylglycerol; DHA, doco-sahexaenoic acid; EPA, eicosapentaenoic acid; 
UMP, uridine monophosphate; vit, vitamin.  
Techniques used in this thesis
Magnetic resonance spectroscopy
MRS allows for the in vivo investigation of brain metabolism and is the predominant technique 
used in the research in this thesis. MRS is closely related to magnetic resonance imaging (MRI), 
well known for its use in the clinic to make images of organs and other soft tissues. The principle 
behind MR is a property of atomic nuclei called spin magnetic moment or ‘spin’ and the use of 
strong magnetic fi elds and radiofrequency (RF) pulses to manipulate those spins24. Only certain 
nuclei have spin and are ‘MR active’. Their spins can be considered as little magnets with a 
fi eld that has a specifi c direction. Outside a magnetic fi eld the billions of spins in the body are 
oriented in all directions. But in a magnetic fi eld the spins will precess around the axis of this 
magnetic fi eld with a specifi c frequency (ω) dependent on the strength of the magnetic fi eld (B0) 
and their intrinsic gyromagnetic ratio (γ). This frequency is called the Larmor frequency and is 
given by: ω = γ·B0. 
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The net magnetization created by all spins is a magnetization vector in the direction of the 
magnetic field. After excitation of the spins by an RF pulse provided by a transmit coil, this 
magnetization vector is tilted in the transverse plane, perpendicular to the main magnetic field. 
In this plane it precesses around the direction of the main magnetic field, also with the Larmor 
frequency. As a result, a current is induced by this rotating net magnetization in a receiver coil. 
This can be compared to the rotation of a magnet in a bicycle dynamo that induces a current 
in a copper wire and produces light. This forms the basis of the MR signal. In MRI the signal of 
protons in water are used to reconstruct an image. Because the human body consists mainly of 
water, a strong signal can be recorded.
MRS makes use of the fact that the exact frequency at which a spin precesses is influenced 
by the chemical environment of the nucleus, because the electrons around the nucleus shield 
it from the external magnetic field25. The Larmor frequency is now given by ω = γ·(1-σ)B0, 
where σ is the shielding constant, which can be different for each nucleus in a molecule. The 
resulting difference in frequency ω is called the chemical shift. This allows for the detection 
and identification of compounds (metabolites), because each compound has a unique set of 
signals (resonances) of nuclei with different chemical shifts. An MR spectrum consists of all 
signals of MR visible nuclei of compounds along a frequency axis given in parts per million 
(ppm) with respect to the Larmor frequency of the main magnetic field. In addition, because the 
integrated resonance area is directly proportional to the concentration of the nucleus and thus of 
the compound, quantification is possible. 
MR spectra can be acquired unlocalized, localized from a single voxel or from multiple voxels 
using MRS imaging (MRSI). The resolution of MRSI is much smaller than the spatial resolution of 
conventional MRI, because the tissue concentration of metabolites is much smaller than that of 
water. Therefore it may be difficult to obtain signal from a single tissue type or from a small area 
of interest. In the brain, one can adjust or correct for this partial volume effect by taking the tissue 
content (gray matter, white matter, cerebrospinal fluid) obtained from structural MR images into 
account. 
In both MR imaging and spectroscopy, proton (hydrogen, 1H) is most often used as the nucleus 
of interest, but in principle any nucleus possessing non-zero spin has a magnetic moment and 
can be investigated. Nuclei besides hydrogen, so-called X-nuclei, that are biologically interesting 
and that possess non-zero spin include phosphorus (31P), carbon (13C), and sodium (23Na). In this 
research, proton and phosphorus magnetic resonance spectroscopy (1H-MRS and 31P-MRS) are 
used. Below a brief description of both techniques will be given, in which only in vivo applications 
of the brain are considered.
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Proton magnetic resonance spectroscopy
MR is most sensitive for hydrogen, because of its high gyromagnetic ratio and its high abundance, 
as many metabolites contain (multiple) protons. Therefore, 1H-MRS is the most commonly used 
MRS technique in both biomedical research and in the clinic26. Furthermore, no special hardware 
is required in addition to conventional MRI, making 1H-MRS possible on any MRI scanner. 
In figure 5 an example 1H-MR spectrum is shown from the posterior cingulate cortex. Each 
metabolite results in one or more peaks at a specific frequency, with the integral of the area 
reflecting the concentration of that metabolite. The major brain metabolites are indicated in the 
figure. N-acetyl-aspartate (NAA) is only present in healthy neurons and is considered a marker 
of neural integrity. Myo-Inositol (mI) arises mainly from glial cells and an increase is associated 
with gliosis. In addition, mI functions as an osmolyte. Phosphocreatine and creatine, important 
in energy metabolism, cannot be separated in common 1H-MRS, and are assessed together as 
total creatine (tCr). Finally, choline containing compounds (tCho) consist of phosphocholine, 
glycerophosphocholine and free choline, and are considered together as a marker of membrane 
turnover and phosphocholine metabolism. 
In AD and its preclinical phase mild cognitive impairment (MCI) levels of NAA are reduced, 
indicative of loss of healthy neurons, while mI is increased, signaling increased gliosis27-29. 
Therefore, the ratio NAA/mI is decreased and is the most sensitive 1H-MRS marker of AD.
Figure 5 
Proton magnetic resonance spectrum from the posterior cingulate cortex of a patient with Alzheimer’s 
disease (67 years old) at 3 tesla. tCr, total creatine; mI, myo-inositol; tCho, total choline; NAA, N-acetyl-
aspartate; ppm, parts per million.
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Figure 6 
Phosphorus magnetic resonance spectrum from the retrosplenial cortex of a patient with Alzheimer’s disease 
(73 years old) at 3 tesla with proton decoupling. Determination of (intracellular) tissue pH is possible from 
the chemical shift difference between PCr and Pi. PEth, phosphoethanolamine; PCh, phosphocholine; Pi, 
inorganic phosphate; GPEth, glycerophosphoethanolamine; GPCh, glycerophosphocholine; MP, membrane 
phospholipids; PCr, phosphocreatine; ATP, adenosine triphosphate; NAD(H), nicotinamide adenine 
dinucleotide; ppm, parts per million.  
Phosphorus magnetic resonance spectroscopy
Although of lower sensitivity than conventional proton MRS, phosphorus can still be assessed 
at the clinical field strength of 3T using dedicated or double-tuned 1H/31P MR hardware. 
31P-MRS provides complementary information to 1H-MRS on membrane turnover (phospholipid 
metabolism) and energy metabolism. Figure 6 shows an example 31P-MR spectrum from 
the retrosplenial cortex. Both phospholipid building blocks (i.e. phosphomonoesters, PME) 
and phospholipid breakdown products (i.e. phosphodiesters, PDE)29,30, are visible in the 31P-
MR spectrum. Because of the interaction of proton spins with the phosphorus spins, the 31P 
peaks may be broadened so that some signals overlap. However, using proton-decoupling 
this interaction can be removed and spectral resolution is improved. As a result, spectral 
fitting of the PMEs phosphocholine (PCh) and phosphoethanolamine (PEth), and of the 
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PDEs glycerophosphocholine (GPCh) and glycerophosphoethanolamine (GPEth) separately 
becomes more reliable. Furthermore, key energy molecules can be assessed in the brain, 
such as adenosine triphosphate (ATP), phosphocreatine (PCr), inorganic phosphate (Pi) and 
nicotinamide adenine dinucleotide (NAD(H)). In addition, tissue pH can be determined from the 
chemical shift difference between the signals of Pi and PCr.
Contents of this thesis
Any drug or nutritional intervention aiming to prevent, reduce, or reverse cognitive symptoms in 
AD must find its way to the circulation and onwards to the brain in order to affect clinical outcome. 
This thesis explores the effects of nutrients in AD, with a focus on those nutrients that are involved 
in phospholipid metabolism, at several levels of this route. 
In chapter 2 the effect of a multi-nutrient intervention, containing phospholipid precursors 
and cofactors (i.e. the medical food Souvenaid®, containing the specific nutrient combination 
Fortasyn® Connect [Nutricia Advanced Medical Nutrition, Utrecht, the Netherlands]), on 
nutritional blood markers in AD is investigated. In a large sample of patients with mild to moderate 
AD, obtained from previously published randomized controlled trials (RCT), the influence of this 
multi-nutrient intervention on circulating levels of vitamins and fatty acids as well as on markers 
of inflammation and oxidative stress is described. Raising circulating levels of the precursors and 
cofactors of phospholipid formation is thought to impact on brain phospholipid metabolism and 
neural integrity. Although neural integrity had been extensively investigated in AD, knowledge 
on phospholipid metabolism was incomplete. As previous studies failed to provide conclusive 
evidence whether alterations are present at the early stage of AD, we investigated phospholipid 
metabolism in mild AD patients and healthy older persons using 31P-MRS in the study described 
in chapter 3. We especially capitalized on recent technical advances in 31P-MRS, such as 
proton-decoupling to increase spectral resolution, and elliptical weighted k-space sampling that 
enabled us to collect whole brain, high quality spectra, within a feasible timeframe. All measures 
could therefore be obtained in multiple brain regions relevant to AD, namely the anterior  and 
posterior parts of the cingulate cortex (ACC and RSC), and the left and right hippocampus 
(HL and HR). Next (chapter 4), we investigated whether phospholipid precursors, or their 
metabolites, would cross the blood brain barrier to affect brain phospholipid metabolism (the 
MRS AD study). In this study, a 4-week double-blind RCT, we used 31P and 1H-MRS to evaluate 
the effect of a multi-nutrient intervention on phospholipid and energy metabolism, and measures 
of neural integrity and gliosis in patients with mild AD. The last step in the route from intake of 
nutrients to clinical efficacy is improved cognition or functional outcome. This was the focus of 
chapter 5, a systematic review in which the added benefit of nutrition to cholinesterase inhibitor 
therapy in AD was investigated. In chapter 6, the results of this thesis are summarized. Finally, 
in chapter 7 the main findings and their implications for future research are discussed.
Processed on: 23-3-2017
509018-L-bw-Rijpma
Chapter 1
20
References
1. World Alzheimer Report 2015. The Global Impact of Dementia: An Analysis of Prevalence, Incidence, 
Cost and Trends Alzheimer’s Disease International (ADI): London.
2. Farooqui, A.A., L.A. Horrocks, and T. Farooqui, Glycerophospholipids in brain: their metabolism, 
incorporation into membranes, functions, and involvement in neurological disorders. Chemistry and 
Physics of Lipids, 2000. 106(1): p. 1-29.
3. Burklen, T.S., et al., The creatine kinase/creatine connection to Alzheimer's disease: CK-inactivation, APP-
CK complexes and focal creatine deposits. Journal of Biomedicine & Biotechnology, 2006. 2006(3): p. 
35936.
4. de la Torre, J.C., Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and 
dialectics. Lancet Neurology, 2004. 3(3): p. 184-190.
5. Burhan, A.M., et al., Role of emerging neuroimaging modalities in patients with cognitive impairment: a 
review from the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. 
Alzheimer's research & therapy, 2013. 5(Suppl 1): p. S4-S4.
6. de Souza, L.C., et al., Neuroimaging in dementias. Current Opinion in Psychiatry, 2012. 25(6): p. 473-
479.
7. Jack, C.R., Jr., et al., Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. 
The Lancet Neurology, 2010. 9(1): p. 119-128.
8. Flicker, L., Modifiable Lifestyle Risk Factors for Alzheimer's Disease. Journal of Alzheimer's Disease, 
2010. 20(3): p. 803-811.
9. Satizabal, C.L., et al., Incidence of Dementia over Three Decades in the Framingham Heart Study. New 
England Journal of Medicine, 2016. 374(6): p. 523-532.
10. Langa, K.M., Is the risk of Alzheimer’s disease and dementia declining? Alzheimer's Research & Therapy, 
2015. 7(1): p. 34.
11. Morris, M.C., The role of nutrition in Alzheimer's disease: epidemiological evidence. European Journal of 
Neurology, 2009. 16: p. 1-7.
12. Morris, M.C., et al., Dietary fats and the risk of incident Alzheimer disease. Archives of Neurology, 2003. 
60(8): p. 1072-1072.
13. Lopes da Silva, S., et al., Plasma nutrient status of patients with Alzheimer's disease: Systematic review 
and meta-analysis. Alzheimers & Dementia, 2014. 10(4): p. 485-502.
14. Bourre, J.M., Effects of nutrients (in food) on the structure and function of the nervous system: update on 
dietary requirements for brain. Part 2 : macronutrients. Journal of Nutrition, Health & Aging, 2006. 10(5): 
p. 386-99.
15. Bourre, J.M., Effects of nutrients (in food) on the structure and function of the nervous system: update on 
dietary requirements for brain. Part 1: micronutrients. Journal of Nutrition, Health & Aging, 2006. 10(5): 
p. 377-85.
16. Beydoun, M.A., H.A. Beydoun, and Y. Wang, Obesity and central obesity as risk factors for incident 
dementia and its subtypes: a systematic review and meta-analysis. Obesity Reviews, 2008. 9(3): p. 204-
218.
Processed on: 23-3-2017
509018-L-bw-Rijpma
GENERAL INTRODUCTION
21
1
17. Sastry, P.S., Lipids of Nervous-Tissue - Composition and Metabolism. Progress in Lipid Research, 1985. 
24(2): p. 69-176.
18. Pettegrew, J.W., et al., Brain membrane phospholipid alterations in Alzheimer's disease. Neurochemical 
Research, 2001. 26(7): p. 771-782.
19. Terry, R.D., et al., Physical basis of cognitive alterations in Alzheimers-disease - Synapse loss is the major 
correlate of cognitive impairment. Annals of Neurology, 1991. 30(4): p. 572-580.
20. Nitsch, R.M., et al., Evidence for a Membrane Defect in Alzheimer-Disease Brain. Proceedings of the 
National Academy of Sciences of the United States of America, 1992. 89(5): p. 1671-1675.
21. Kennedy, E.P. and S.B. Weiss, The function of cytidine coenzymes in the biosynthesis of phospholipides. 
The Journal of Biological Chemistry, 1956. 222(1): p. 193-214.
22. Cansev, M., et al., Oral administration of circulating precursors for membrane phosphatides can promote 
the synthesis of new brain synapses. Alzheimer's & Dementia, 2008. 4(1): p. S153-S168.
23. Olde Rikkert, M.G., et al., Differences in nutritional status between very mild Alzheimer's disease patients 
and healthy controls. Journal of Alzheimer's disease, 2014. 41(1): p. 261-71.
24. Huettel, S.A., A.W. Song, and G. McCarthy, Functional magnetic resonance imaging. 2004, Sunderland, 
Massachusetts U.S.A.: Sinauer Associates, Inc.
25. de Graaf, R., In vivo NMR spectroscopy. Principles and techniques. Second Edition ed. 2008, Chichester 
John Wiley.
26. Oz, G., et al., Clinical Proton MR Spectroscopy in Central Nervous System Disorders. Radiology, 2014. 
270(3): p. 658-679.
27. Tumati, S., S. Martens, and A. Aleman, Magnetic resonance spectroscopy in mild cognitive impairment: 
systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews, 2013. 37(10 Pt 2): p. 
2571-86.
28. Graff-Radford, J. and K. Kantarci, Magnetic resonance spectroscopy in Alzheimer's disease. 
Neuropsychiatric Disease and Treatment, 2013. 9: p. 687-96.
29. Martin, W.R.W., MR Spectroscopy in neurodegenerative disease. Molecular Imaging and Biology, 2007. 
9(4): p. 196-203.
30. Pettegrew, J.W., Molecular Insights into Alzheimer's Disease. Annals of the New York Academy of 
Sciences, 1989. 568(1): p. 5-28.
Processed on: 23-3-2017
509018-L-bw-Rijpma
Processed on: 23-3-2017
509018-L-bw-Rijpma
Published as: Anne Rijpma, Olga Meulenbroek, Anneke M.J. van Hees, John W.C. Sijben, 
Bruno Vellas, Raj C. Shah, David A. Bennett, Philip Scheltens, Marcel G.M. Olde Rikkert, 2015. 
Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and 
mild-to-moderate Alzheimer’s disease. 
Alzheimer’s Research & Therapy, 7 (1), 51
2
 Effects of Souvenaid on plasma micronutrient levels 
and fatty acid profiles in mild and mild-to-moderate 
Alzheimer’s disease 
Processed on: 23-3-2017
509018-L-bw-Rijpma
Chapter 2
24
Abstract 
INTRODUCTION: Circulating levels of uridine, selenium, vitamins B12, E and C, folate, 
docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) have been shown to be lower in 
patients with Alzheimer’s disease (AD) than in healthy individuals. These low levels may affect 
disease pathways involved in synapse formation and neural functioning. Here, we investigated 
whether, and to what extent, circulating levels of micronutrients and fatty acids can be affected 
by oral supplementation with Souvenaid (containing a specific nutrient combination), using data 
derived from three randomized clinical trials (RCT) and an open-label extension (OLE) study with 
follow-up data  from 12 to 48 weeks. 
METHODS: Subjects with mild (RCT1, RCT2) or mild-to-moderate AD (RCT3) received active or 
control product once daily for 12–24 weeks or active product during the 24-week OLE following 
RCT2 (n = 212–527). Measurements included plasma levels of B vitamins, choline, vitamin 
E, selenium, uridine and homocysteine and proportions of DHA, EPA and total n-3 long-chain 
polyunsaturated fatty acids in plasma and erythrocytes. Between-group comparisons were 
made using t tests or non-parametric alternatives. 
RESULTS: We found that 12–24-week active product intake increased plasma and/or erythrocyte 
micronutrients: uridine; choline; selenium; folate; vitamins B6, B12 and E; and fatty acid levels 
of DHA and EPA (all p < 0.001). In the OLE study, similar levels were reached in former control 
product / initial active product users, whereas 24-week continued active product intake showed 
no suggestion of a further increase in nutrient levels. 
CONCLUSIONS: These data show that circulating levels of nutrients known to be decreased in 
the AD population can be increased in patients with mild and mild-to-moderate AD by 24–48-
week oral supplementation with Souvenaid. In addition, to our knowledge, this is the first report 
of the effects of sustained dietary intake of uridine monophosphate on plasma uridine levels in 
humans. Uptake of nutrients is observed within 6 weeks, and a plateau phase is reached for most 
nutrients during prolonged intake, thus increasing the availability of precursors and cofactors in 
the circulation that may be used for the formation and function of neuronal membranes and 
synapses in the brain.
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Introduction
Several disease pathways and risk factors for Alzheimer’s disease (AD) are hypothesized to be 
affected by nutritional factors, such as reduced neuronal membrane integrity and function, and 
phospholipid metabolism1-3. Correspondingly, epidemiological studies have repeatedly shown 
the protective and/or risk reducing effects of nutritional intake on AD4-6. In addition, patients with 
AD are frequently reported to have lower plasma levels of certain nutrients than healthy controls7-10. 
Data derived from our own studies have shown lower plasma levels of uridine, selenium, and 
docosahexaenoic acid (DHA) in patients with mild AD than in healthy age matched controls10. 
A recent meta-analysis showed lower levels in folate, and vitamins A, B12, C, and E in patients 
with AD than in healthy controls7. Together, these studies suggest a connection between nutrient 
status and AD. Counteracting any nutritional deficiencies may therefore have a beneficial effect 
on patients with AD. 
The medical food Souvenaid, which contains the specific nutrient combination Fortasyn Connect 
(both products of Nutricia Advanced Medical Nutrition, Utrecht, the Netherlands), has been 
designed to address the distinct nutritional needs of patients with AD and thereby ameliorate 
synapse loss and synaptic dysfunction in AD. The medical food was developed to increase 
brain levels of specific nutrients to support the process of neuronal membrane formation11. In 
turn, increased brain nutrient levels can stimulate synapse formation to compensate for synapse 
loss in AD12,13. A prerequisite for potentially raising brain nutrient levels is that the intervention will 
indeed raise circulating nutrient levels, thus increasing their availability for neuronal membrane 
formation. 
A number of clinical trials have been performed to investigate the effect of this specific nutrient 
combination on cognitive function in patients with mild AD14,15 (referred to hereinafter as RCT1 
and RCT2, respectively) and those with mild-to-moderate AD16 (referred to hereinafter as RCT3). 
One open-label extension (OLE) study (extension of RCT2) has been performed with safety as 
the primary endpoint and memory as an exploratory endpoint. Both trials in drug-naïve patients 
with mild AD showed improvement in memory domain scores after 12 weeks (RCT1) and 24 
weeks (RCT1 and RCT2)14,15,17. The OLE showed that use of this specific nutrient combination for 
up to 48 weeks was well tolerated. Furthermore, a significant increase in the exploratory memory 
outcome was observed in both the active-active and control-active-groups from 24 to 48 weeks 
of use18. In the clinical trial in patients with mild-to-moderate AD and on AD medication, no 
change in cognitive function was found after 24 weeks (RCT3) 16. 
Blood samples were taken at baseline and at the end of the study in all RCTs. Here, we investigate 
whether, and to what extent, circulating levels of micronutrients and fatty acids, among which 
several are known to be decreased in the AD population, are affected by 12-48-week oral 
supplementation with Souvenaid, in patients with mild and mild-to-moderate AD. 
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Methods
Three double-blind, multicenter, controlled RCTs (Souvenir [RCT1], Souvenir II [RCT2] and 
S-Connect [RCT3]) were performed between 2006 and 2011, to evaluate the effects of the 
medical food Souvenaid on cognition and memory performance in patients with AD14-16. Subjects 
who completed the 12-week intervention of RCT1 were invited to participate in a 12-week double-
blind extension period. In addition, an RCT2 OLE study was performed between 2010 and 2012 
to evaluate longer-term safety of and compliance with Souvenaid19. Here we present the results 
of the analyses of secondary and exploratory plasma micronutrient parameters and fatty acid 
profiles in plasma, plasma phospholipids and erythrocyte membranes. Some results have been 
reported previously in publications describing the results of the RCTs, mainly as compliance 
markers14-16,19. All trials were registered in the Dutch Trial Register (Souvenir: NTR702; Souvenir II: 
NTR1975; S-Connect: NTR1683; and OLE: NTR2571).
Study population
The study population and methodology of the studies have been described in detail previously14-16,19. 
Briefly, all studies included men and women ≥ 50 years of age who were diagnosed with probable 
AD according to the National Institute of Neurological and Communicative Disorders and Stroke-
Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria 20 and were 
either in the mild stage of AD as defined by Mini Mental State Examination (MMSE) scores of 
20-26 (RCT1) or ≥ 20 (RCT2), or in the mild to moderate stage of AD, defined as an MMSE score 
of 14-24 inclusive (RCT3). Subjects in RCT1 and RCT2 had to be drug-free for AD medication, 
whereas subjects in RCT3 were on a stable dose of approved AD medication. Subjects were 
not allowed to use, within 1–2 months before study participation and during the study, fatty acid 
containing supplements (RCT1, RCT2, and RCT3), consume oily fish more than twice per week 
(RCT 2 and RCT3), use vitamins B, C and/or E >200% (RCT1 and RCT2) or >100% (RCT3) of 
recommended dietary allowance (RDA)21,22; or to use high-energy and/or high-protein nutritional 
supplements and/or medical foods (RCT2 and RCT3). At the end of RCT2, all subjects who 
completed the study were invited to participate in the OLE. Eligibility criteria for the OLE allowed 
patients to use AD medication and nutritional supplements.
Study procedures
All subjects were randomly assigned to receive the active or control product once-daily during 
12 weeks (RCT1) or 24 weeks (RCT1 extension, RCT2, RCT3), whereas during the OLE study, 
all subjects received the active product. The active product (Souvenaid) contains the specific 
nutrient combination Fortasyn Connect (Table 1). The control product is iso-caloric and similar in 
appearance and flavor to the active product, but without Fortasyn Connect. Both study products 
were available in the form of a 125 ml drink (125 kcal) in vanilla or strawberry flavors (RCT2, RCT3 
and OLE) and peach orange or cappuccino flavor (RCT1).
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Table 1 Nutritional composition of the study products; amount per daily dose (125 mL)
Control Active
Energy 125 kcal 125 kcal
Protein 3.8 g 3.8 g
Carbohydrate 16.5 g 16.5 g
Fat 4.9 g 4.9 g
EPA 0 300 mg
DHA 0 1200 mg
Phospholipids 0 106 mg
Choline 0 400 mg
UMP 0 625 mg
Vitamin E (alpha-TE) 0 40 mg
Vitamin C 0 80 mg
Selenium 0 60 µg
Vitamin B12 0 3 µg
Vitamin B6 0 1 mg
Folic acid 0 400 µg
EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; UMP, uridine monophosphate; TE, tocopherol 
equivalents.
Study staff, subjects and caregivers were blinded to each subject’s randomized study group 
allocation throughout all studies, including the extension of RCT1 and the OLE (i.e. blinding for 
group allocation during RCT2 continued).
Outcome parameters for the current analyses were assessed at baseline and, depending on the 
nutrient, week 24 of RCT1, RCT2 and RCT3 and at week 24 (presented as week 48) of the OLE. The 
screening/baseline visit for the OLE was combined with the final visit (week 24) of RCT2. In addition, 
homocysteine (Hcy), vitamin E, uric acid and percentages of DHA, eicosapentaenoic acid (EPA) and 
docosapentaenoic acid (DPA) of total fatty acids in erythrocyte membrane also were assessed at 
week 6 and week 12 of RCT1. These are not statistically analyzed in the present article. However, data 
on percentage DHA of total fatty acids in erythrocyte membrane is shown in Figure 1.
Written informed consent was obtained from subjects and their caregivers before study 
participation. The ethics committee of each participating study center in each study reviewed 
and approved the protocol (see Additional file 1). The studies were conducted in accordance 
with the Declaration of Helsinki, the International Conference on Harmonization Guidelines for 
Good Clinical Practice as appropriate for nutritional products and the local laws and regulations 
of the country in which the research was conducted.
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Study parameters
Fasting (RCT1) and non-fasting (RCT2, RCT3, and OLE) venous blood samples were taken to 
determine plasma levels of folate, Hc), vitamins B6 and B12, choline, vitamins D and E, selenium, 
uridine and fatty acids (including DHA, EPA, DPA and total n-3 long-chain polyunsaturated fatty 
acids [n-3 LC-PUFA]). In addition, erythrocytes were collected to determine fatty acid (including 
DHA, EPA, DPA and n-3 LC-PUFA) levels in the erythrocyte membrane. In RCT1, the results in 
plasma vitamin C analyses varied greatly, preventing meaningful interpretation. For that reason, 
in RCT2 and RCT3, vitamin C levels were not analysed. In RCT1, venous blood samples also 
were taken to determine plasma levels of uracil, uric acid, cytidine, malondialdehyde (MDA), 
(pre)albumin, C-reactive protein (CRP), interleukin (IL)-1β, IL-6, IL-10 and 8-isoprostane.
Parameters were assessed in the intention-to-treat (ITT) population or in subgroups, based on 
the availability of blood samples. The actual number of analyzed samples is indicated in the 
tables and Figure 1 for each parameter.
Information on preexisting and new use of medication and nutritional supplements was collected 
throughout the studies.
Biochemical analyses
Blood was collected in tubes containing ethylenediaminetetraacetic acid. All samples were 
centrifuged (1300 g, 15 min, 4°C), and plasma and erythrocyte aliquots were stored at -70 °C / 
-80 °C (RCT1, RCT2 and OLE) or at least -20 °C (RCT3) until analysis at a central laboratory. For 
RCT2 and the OLE, all baseline and 24-week samples were analyzed together as part of RCT2, 
whereas all 48-week samples were analyzed at the end of the OLE.
Plasma folate and vitamin B12 levels were determined using a competitive protein binding ligand 
assay. Plasma B6 levels were measured by performing high-performance liquid chromatography 
(HPLC). HPLC electrochemical detection of plasma-free choline was performed according to a 
method adapted from one previously described by Fossati et al.23 and as reported previously24. 
Plasma albumin was determined using a colorimetric kit, plasma selenium levels were measured 
using graphite furnace atomic absorption spectrometry and plasma pre-albumin and CRP 
levels were assessed using turbimetric assays. A microparticle chemiluminescent microparticle 
immunoassay (ARCHITECT assay; Abbott Diagnostics, Lake Forest, IL, USA) was used to 
determine plasma vitamin D (total 25-hydroxyvitamin D) levels. Plasma vitamin E levels were 
determined by performing HPLC using fluorometric properties for detection of α-tocopherol by 
comparison with standard solutions25. For the determination of plasma Hcy levels, thiol amino 
acids (free and protein-bound) were reduced with tri-n-butylphosphine. After precipitation 
with trichloroacetic acid, thiol groups were derivatized with ammonium 7-fluorobenzo-2-oxa-
1,3-diazole-4-sulfonate, followed by separation using HPLC with a fluorescence detector26,27. 
Determination of MDA was based on the thiobarbituric acid and reversed-phase HPLC 
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separation with fluorescence detection28. To determine plasma uridine, uracil and cytidine levels, 
perchloric acid was added to the sample. Uridine, uracil and cytidine were extracted by vortexing 
the solution, followed by separation from other nucleotides/nucleosides using reversed-phase 
HPLC29. The compounds were quantified by measuring its absorbance compared with a standard. 
Uric acid levels in plasma were determined using an enzymatic assay. Plasma levels of cytokines 
(IL-1β, IL-6 and IL-10) and free 8-isoprostane were measured using, respectively, a commercial, 
custom-made human Bio-Plex cytokine bead-based immunoassay (Bio-Rad Laboratories, 
Hercules, CA, USA) and a commercially available enzyme immunoassay (Cayman Chemical, 
Ann Arbor, MI, USA) according to the manufacturers’ protocol. The fatty acid composition of the 
total lipid fraction in plasma and erythrocytes was analyzed qualitatively on a gas chromatograph 
after extraction of the lipids from the plasma and/or erythrocytes and a methylation step30-33.
Statistical analyses
Analyses were performed on the ITT population for each study or on subgroups, based on the availability 
of samples. Changes in outcome parameters over time were compared between groups using an 
independent samples t-test and/or within groups using a paired t-test. Non-parametric alternatives 
(Mann-Whitney U test and Wilcoxon signed-rank test) were used for non-normal distributions. For RCT2 
and the OLE, sensitivity analyses were performed for vitamin B6, vitamin B12, folate, choline and Hcy 
excluding two patients in the control-active group because of their recent use of vitamin B12 injections 
prior to baseline, which might have interfered with plasma levels of these parameters. In addition, 
the impact of sex and age as covariates and as modifiers of the intervention effect on the laboratory 
parameters of RCT2 was tested using analysis of covariance (ANCOVA) with change from baseline as 
a dependent variable and baseline as an additional covariate. For these analyses, several parameters 
were log transformed to get a distribution closer to the normal distribution.
Statistical analyses were performed using SAS® software (SAS Enterprise Guide 4.3 for Windows, 
SAS Institute, Cary, NC, USA). Data are presented as means ± standard deviation (SD) unless 
stated otherwise. OLE data are presented according to the intervention received during the 
double-blind study period of RCT2 (i.e. control-active and active-active). Statistical significance 
was set at p<0.05 and was not corrected for multiple testing. 
Results
The baseline characteristics of the total study population (RCT1: n=212, RCT2: n=259, RCT3: 
n=527 and OLE: n=201), are summarized in Table 2. By definition, all studies included a mild or 
mild-to-moderate AD population (mean MMSE scores of 23.9 [RCT1], 25.0 [RCT2], 19.5 [RCT3] 
and 25.1 [OLE]), and all subjects were aged 50 years or older (range: 50 - 95 years; mean age 
73.7 years [RCT1], 73.8 years [RCT2], 76.7 years [RCT3] and 74.2 years [OLE] years). 
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There were no significant or relevant between-group differences in use of nutritional supplements 
during the studies, except for the use of vitamin C in RCT3, which was significantly higher in the 
active group versus the control group (2.3% [n=6] versus 0% [n=0], p=0.030). In RCT3, a large 
proportion (41.2%) of subjects used (multi-)vitamins.
Plasma micronutrients and fatty acids available in Fortasyn Connect
Descriptive statistics for plasma micronutrients and erythrocyte fatty acids available in Fortasyn 
Connect are presented in Table 3. Results for plasma vitamin E and erythrocyte DHA and EPA 
have been published in part before14-16,19. 
Plasma levels of uridine, choline, folate, vitamins B6 and B12, selenium and vitamin E were all 
significantly increased in the active vs. control group from baseline to Week 24 in RCT1, RCT2 
and RCT3 ( all: p<0.001, except for uridine in RCT1 [p=0.044], Mann-Whitney U test) (Table 3). 
During the OLE, plasma levels of these parameters were significantly increased in the control-
active group from week 24 to week 48 (i.e. after switching to the active product upon entry into 
the OLE study) (all: p<0.001, Wilcoxon signed-rank test). In addition, plasma levels remained 
consistently elevated in the active-active group during the OLE, except for plasma levels of 
uridine, vitamin B12 and selenium, which significantly decreased in the active-active group from 
week 24 to week 48 (Table 3). Despite the latter, however, there was a significant overall increase 
in plasma uridine and selenium, but not vitamin B12, from baseline to week 48 in the active-
active group (p<0.001, Wilcoxon signed-rank test).
In line with the above described data, the percentages DHA and EPA of total fatty acids in 
both plasma and the erythrocyte membrane also were significantly increased in the active vs. 
control group from baseline to Week 24 in RCT1, RCT2 and RCT3 (p<0.001, t-test [RCT 1] or 
Mann-Whitney U test [RCT2 and RCT3]) (Table 3, Figure 1). During the OLE, levels remained 
consistently elevated in the active-active group and significantly increased in the control-active 
group from week 24 to week 48 (p<0.001, Wilcoxon signed-rank test) (Table 3, Figure 1). The 
results for n-3 LC-PUFA in plasma and erythrocytes in RCT2, RCT3 and OLE, were all in line with 
the results for the individual fatty acids DHA and EPA.
Comparable results were obtained from the sensitivity analyses of plasma choline, folate and 
vitamins B6 and B12.
A modifying intervention effect of sex on log-transformed percentage of EPA in erythrocyte 
membrane was found in RCT2 (p=0.021, ANCOVA). Post-hoc analyses revealed significantly 
increased percentages of EPA in the active versus control group from baseline to week 24 for 
both men and women, but the effect was larger in women than in men (treatment effects of 0.446 
for women [p<0.001, t test] and 0.343 for men [p<0.001, t test]). No other effects of sex were 
found. Age was neither a significant covariate nor a significant intervention modifier for any of the 
micronutrients or fatty acids in RCT2.
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Table 4 Descriptive statistics for plasma markers of inflammation and oxidative stress; RCT 1.
Baseline Week 24 P-value *
CRP (mg/L)
Control 1.75 [0.00, 66.90] (44) 1.80 [0.20, 58.90] (45) 0.686
Active 2.00 [0.10, 17.40] (47) 1.80 [0.10, 16.40] (47)
IL-1β (pg/mL)
Control 0.24 [0.20, 0.66] (25) 0.24 [0.20, 1.48] (23) 0.309
Active 0.24 [0.20, 0.68] (30) 0.24 [0.20, 0.82] (25)
IL-6 (pg/mL)
Control 2.67 [0.23, 108.3] (26) 2.59 [0.93, 6.63] (23) 0.733
Active 2.65 [0.26, 8.65] (31) 3.20 [0.31, 10.62] (25)
IL-10 (pg/mL)
Control 0.91 [0.40, 2.63] (25) 1.01 [0.31, 1.72] (23) 0.799
Active 1.06 [0.05, 2.88] (32) 1.00 [0.11, 2.68] (27)
8-isoprostane (pg/mL)
Control 17.78 [4.55, 80.85] (25) 22.12 [8.81, 38.40] (23) 0.071
Active 19.06 [6.01, 36.32] (30) 17.66 [5.73 - 35.66] (25)
MDA (µmol/L)
Control 1.23 (0.53) [45] 1.45 (0.57) [45] 0.786 #
Active 1.22 (0.56) [47] 1.48 (0.54) [47]
Data are mean (SD) [n] or median [min, max] (n).
* Mann-Whitney test, change from baseline at Week 24, control vs. active.
# Independent samples t-test, change from baseline at Week 24, control vs. active.
Plasma markers of inflammation and oxidative stress
Plasma markers of inflammation (CRP, IL-1β, IL-6 and IL-10) and oxidative stress (8-isoprostane 
and MDA) were measured at baseline and week 24 in subgroups of the RCT1 study population. 
No statistically significant between-group differences were observed for the change in any of 
these parameters (Table 4).
Other micronutrients and fatty acids 
Results for plasma Hcy have been published in part before14-16,19. They showed significantly 
decreased levels in the active group versus the control group from baseline to week 24 in RCT1, 
RCT2 and RCT3 (p<0.001 [RCT1 and RCT2] and p=0.004 [RCT3], Mann-Whitney U test). 
During the OLE, plasma Hcy levels were significantly decreased from week 24 to Week 48 in the
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Figure 1 
Docosahexaenoic acid (DHA) of total fatty acids in erythrocyte membrane (%) in randomized clinical trial 
1 (RCT1), RCT2, RCT3 and the open-label extension (OLE) study in the active and control groups. RCT1, 
Mean±SD; RCT2,3 and OLE, boxplots show median values (solid horizontal line), 25th-75th percentile 
values (box outline) and minumum and maximum values (whiskers). Dashed lines connect median values 
between time points within groups
control-active group (p<0.001, Wilcoxon signed-rank test), and continued to decrease within the 
active-active group (p<0.001, Wilcoxon signed-rank test).
The percentage DPA of total fatty acids in the erythrocyte membrane was significantly decreased 
in the active versus the control group from baseline to week 24 in RCT2 and RCT3 (p<0.001, 
Processed on: 23-3-2017
509018-L-bw-Rijpma
EffEcts of souvEnaid on plasma in alzhEimEr’s disEasE
37
2
Mann-Whitney U test). During the OLE, levels remained consistently decreased in the active-
active group and significantly decreased in the control-active group from week 24 to week 48 
(p<0.001, Wilcoxon signed-rank test). 
For plasma levels of uracil, uric acid, pre-albumin (RCT1), vitamin D and DPA (RCT2), and 
albumin (RCT1 and RCT2), no statistically significant between-group differences were observed 
for the change in any of these parameters (data not shown). Cytidine was not detectable in the 
plasma samples using the current laboratory method.
Discussion
Circulating levels of micronutrients and fatty acids, including uridine, selenium, folate, vitamin 
B12, vitamin E, vitamin C, DHA and EPA, are reported to be decreased in the AD population 
and can be increased by 12-48-week oral supplementation with Souvenaid. All micronutrients 
and fatty acids present in this specific nutrient combination (containing Fortasyn Connect) show 
increased plasma (and erythrocyte for fatty acids) concentrations after 24 weeks of daily use 
of active product versus control product in patients with mild and mild to moderate AD, except 
for vitamin C which could not be reliably measured. Most nutrients remain unchanged during 
prolonged intake for another 24 weeks. Data derived from RCT1 on vitamin E and percentage 
DHA and EPA of total fatty acids in erythrocyte membrane suggest that circulating levels are 
increased already at week 6 and that a plateau is reached within 12 weeks of daily intake (shown 
for DHA in Figure 1, upper left panel). This is supported by studies showing rising plasma levels 
within hours of administration of, for example, UMP11, vitamin C34, and vitamin E35. Together these 
findings suggest that other micronutrients investigated in this study might follow a similar pattern 
of increase, as shown for the percentage DHA in the erythrocyte membrane (Figure 1). 
All components of Fortasyn Connect are precursors or cofactors required for neuronal membrane 
formation36. Increasing availability of all substrates for the formation of phosphatidylcholine (PC) and 
phosphatidylethanolamine (PE) is important to enable neuronal membrane synthesis and ultimately 
support synapse maintenance and/or promote synapse formation13,37. Increases in the substrates 
could underlie the improvement in memory domain scores that were found in the trials in drug-naïve 
patients with mild AD after 12 weeks (RCT1), 24 weeks (RCT1, RCT2, and OLE) and the exploratory 
data for the additional 24 weeks (OLE)14,15,18. No change in cognition was found, however, after 24 
weeks in the clinical trial in patients with mild-to-moderate AD and on AD medication (RCT3)16. These 
results suggest that early intervention is likely key to an effect on cognition.  
This is the first study, to the best of our knowledge, in which the effects of sustained dietary intake 
of UMP on plasma uridine levels in humans are reported. We showed previously that intake of 
a single serving of 625 mg UMP by healthy human subjects resulted in peak plasma uridine 
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concentration of 14.6 µmol/L at 1 hour after intake11. The present data indicate that daily intake 
of the same UMP-containing intervention for 24 and 48 weeks increases fasting (RCT1) and non-
fasting (RCT2, RCT3, OLE) plasma uridine in people with AD. This new observation is particularly 
relevant in view of recent studies which indicate that plasma uridine10,38 and cerebrospinal fluid 
(CSF) uridine39,40 levels are lower in AD than in controls. Other investigations indicated that 
circulating and brain levels of DHA and choline are lower in people with AD than in controls41-44. 
The results of the present study indicate that, in addition to uridine, the investigational product 
increases circulating DHA and choline, a finding in line with other intervention studies showing  that 
supplemental dietary DHA and choline increase their circulating levels in various populations45-48. 
Uridine together with DHA and choline are the rate-limiting precursors via the Kennedy pathway 
for the synthesis of phospholipids in neuronal membranes, which are depleted in AD49,50. As 
combined dietary enrichment of these nutrients has been reported to promote the synthesis of 
brain phospholipids, hippocampal dendritic spines, and synaptic proteins, all prerequisites for 
synaptogenesis51, repletion of DHA, choline and uridine may therefore contribute to counteract 
the characteristic synaptic loss in AD. Tissue target levels of DHA, choline and uridine are not 
well defined for the general population; however, given their role in neuronal membrane synthesis 
people with AD likely require higher levels to compensate for membrane loss. The present study 
indicates that the investigated intervention is efficacious in enhancing circulating levels of these 
nutrients in AD.  
In RCT1, markers of inflammation and oxidative stress were measured as exploratory outcomes 
to investigate whether the n-3 LC-PUFA and the antioxidants vitamins C and E had a direct effect 
on inflammation or oxidative stress, respectively.  No changes were found, however, in plasma 
markers of inflammation (CRP, IL-1β, IL-6 and IL-10) or oxidative stress (8-isoprostane and MDA) 
in a subgroup of the RCT1 population after 24 weeks intake of this specific nutrient combination 
compared with a control product. Similarly to Freund-Levi et al.52, who did not find an effect 
on inflammatory markers in either plasma or CSF, we found no effects on any of the markers 
of inflammation, even though the current intervention contained two to three times greater 
amounts of DHA and EPA. In some studies in which researchers did find an effect of antioxidant 
supplements on markers of oxidative stress in patients with AD contained much higher doses of 
for example vitamin E (3500 % versus 400% of RDA)53 than those used in the current study, while 
others used comparable dosages (200% RDA)54. Differences still exist however in the timing and 
duration of the intervention, and in the method used to measure oxidative stress. These results 
suggest that changes in cognition found in the trials and the OLE were not due to mediation of 
inflammation or oxidative stress. 
As expected on the basis of equal amounts of vitamin D, protein and energy contained in the 
active and control product, plasma levels of prealbumin (RCT1), vitamin D (RCT2), and albumin 
(RCT1 and RCT2) were not altered by intake of this specific nutrient combination. 
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Plasma Hcy levels were significantly decreased after 24 weeks in the active group and continued 
to decrease with prolonged intake. This is in line with the observed increases in vitamin B6 
and B12, and folic acid levels. Increased B-vitamin levels and decreased Hcy levels enhance 
methylation capacity, thereby increasing PE to PC conversion by the PE-N-methyltransferase 
(PEMT) pathway in the liver. This leads to increased availability of choline and DHA-rich PC for 
(neuronal) membrane synthesis24,55. In addition, decreased Hcy levels may indicate improved 
vascular health. Previous animal studies showed increased cerebral blood flow in a 12 month 
old mouse model of AD fed this specific nutrient combination compared with a control diet56. 
The increase in percentage EPA of total fatty acids in erythrocyte membrane after 24 weeks in 
the active group in RCT2 was larger in women than in men. This could be a true sex difference, 
as Burdge et al.57,58 showed a higher conversion rate of α-linolenic acid to EPA (and DHA) in 
young women than in young men, or it could be due to differences in body weight. Flock et al.59 
showed that body weight significantly improved prediction of treatment response of EPA+DHA 
supplements on erythrocyte membrane content of EPA compared with dose only. However, a 
trend for an increased treatment response in women compared with men was found in this same 
study, while already correcting for body weight, suggesting an effect of sex independent from 
body weight. Despite the uncertainty about the underlying mechanism, the incorporation of EPA 
in erythrocyte membrane is apparently greater in our population of elderly women with AD than 
in men, although it was significant in both sex groups.
DPA erythrocyte (but not plasma, RCT2) concentrations were decreased from baseline to week 
24 in the active group compared with the control group in RCT2 and 3, and reached a plateau 
in the OLE at week 48. Possibly the increasing availability of the two other major n-3 LC-PUFAs, 
DHA and EPA, reduces the incorporation of DPA in erythrocytes while plasma levels remain 
stable60.
The data presented in this article on the increased levels of multiple nutrients and fatty acids 
are generally in line with known kinetics of single nutrients, which assures that there is no 
relevant interaction in absorption. We found consistent results over three large RCTs when we 
evaluated the ITT population, representing patients with both mild and mild–to-moderate AD, 
and including patients using AD medication as well as drug-naïve patients. However, we report 
on exploratory analyses and none of our outcome measures were primary endpoints of the 
studies. Furthermore, it should be noted that the present data refer only to circulating levels, 
whereas the nutrients should have their effect in the brains of patients with AD. With the current 
data we cannot confirm whether these nutrients or their metabolites cross the blood-brain barrier 
and have an effect on synapse synthesis and maintenance. Evidence exists, however, to support 
the proposed mechanism of action. On the basis of tracing studies done with positron emission 
topography (PET), we know that at least the precursors for the Kennedy pathway, i.e. choline, 
DHA and uridine  do reach the brain within hours of administration in animals and/or healthy 
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humans61-63. For instance, Umhau et al.62 showed that, based on PET measurements 60 minutes 
following administration of [1-11C]DHA, the incorporation rate of DHA could be calculated in 
healthy human volunteers. Additionally, in a subset of the study population of RCT2 additional 
electroencephalographic measurements were performed to assess underlying synaptic 
function. We found preserved organization of brain networks in patients with mild AD within 24 
weeks, compared with a control product, hypothetically counteracting the progressive network 
disruption over time in AD64. Currently, a study of drug-naïve patients with mild AD is ongoing 
to investigate the effect of this specific nutrient combination on brain phospholipid metabolism 
by phosphorus magnetic resonance spectroscopic imaging (MRSI)65. In contrast to the present 
study, this MRSI study will provide more direct evidence on the extent to which the nutrients and 
their metabolites can affect neuronal membrane turnover and influence synaptic function.
Conclusion 
These data show that circulating levels of nutrients, known to be decreased in the AD 
population, can be increased in patients with mild and mild-to-moderate AD by 24-48 weeks 
oral supplementation with Souvenaid. Uptake is observed within 6 weeks and a plateau phase is 
reached for most nutrients during prolonged intake, thus increasing the availability of precursors 
and cofactors necessary for the formation and function of neuronal membranes and synapses for 
the brain. This adds to the rationale of using oral supplementation of micronutrients to replenish 
nutritional deficits in patients with AD.
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For site 007: University of Texas Health Science Center, IRB 
For site 001: Rush University Medical Center, IRB 
For site 016: Wake Forest University Health Sciences, IRB 
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002 - Mulroy Amy E. Clinical Trials of Texas Inc., San Antonio, TX 
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004 - Hyman Lawrence R Howard Behavioral Health Inc. Columbia Medical Center, 
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005 - Schwartz Matthew T Behavioral Medical Research of Brooklyn, Brooklyn, NY 
006 - Morley John E Saint Louis University Medical Center, St. Louis, MO 
007 - Royall Donald R. University of Texas Health Science Center, San Antonio, TX 
008 - Huege Steven F Penn Memory Center University of Pennsylvania, Philadelphia, PA 
010 - Antuono Piero G Medical College of Wisconsin, Milwaukee, WI 
011 - Quinn Joseph Oregon Health and Science University Aging and Alzheimer 
Disease Center, Portland, OR 
012 - Raj Ashok Byrd Alzheimer's Institute Tampa, FL 
013 - Baker Matthew J. Collier Neurologic Specialists, Naples, FL 
014 - Burns Jeffrey M. University of Kansas Medical Center - Department of Neurology, 
Kansas City, KS 
016 - Sink Kaycee Kylynych Center for Memory & Cognition Research Wake Forest 
University Health Sciences, Winston-Salem, NC 
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017 - Kudrow David David Kudrow MD, Santa Monica, CA 
020 - Shua-Haim Joshua R Alzheimer's Research Corporation, Manchester, NY 
021 - Knesevich Mary Ann Mary Ann University Hills Clinical Research, Irvine, TX 
022 - Breving Joel T Behavioral Medical Research of Staten Island, Staten Island, NY 
023 - Omidvar Omid Collaborative Neuroscience Network, Garden Grove, CA 
024 - Jones Beverly Nicholas Clinical Trials of America Inc, Winston-Salem, NC 
025 - Duboff Eugene Radiant Research, Denver, CO 
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028 - Cohen Steven R. Suncoast Neuroscience Associates INC, St. Petersburg, FL 
029 - McElveen William Alvin Bradenton Research Center, Bradenton, FL 
032 - Randhawa Surinder K. Lynn Health Science Institute, Oklahoma City, OK 
033 - Weiss Thomas R. Radiant Research, San Antonio San Antonio, TX 
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Abstract
Defects in essential metabolic processes for energy supply and phospholipid membrane 
function have been implicated in Alzheimer’s disease (AD). Post-mortem investigations are 
generally limited to late stage disease and prone to tissue decay artifacts. In vivo assessments 
of high energy phosphates, tissue pH and phospholipid metabolites are possible by phosphorus 
MR spectroscopy (31P-MRS), but so far only small studies, mostly focusing on single brain 
regions, have been performed. Therefore, we assessed phospholipid and energy metabolism in 
multiple brain regions of 31 early stage AD patients and 31 age- and gender-matched controls 
using 31P-MRS. An increase of phosphocreatine (PCr) was found in AD patients compared with 
controls in the retrosplenial cortex, and both hippocampi, but not in the anterior cingulate cortex. 
While PCr/inorganic phosphate and pH were also increased in AD, no changes were found for 
phospholipid metabolites. This study showed that PCr levels are specifically increased in regions 
that show early degeneration in AD. Together with an increased pH, this indicates an altered 
energy metabolism in mild AD.
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Introduction
Alzheimer’s disease (AD) is the main cause of dementia in the elderly, responsible for about 
half of the nearly 47 million dementia cases worldwide1. Although the disease is defined by 
the accumulation of amyloid beta plaques and neurofibrillary tau tangles in the brain2, other 
pathological processes can be identified such as oxidative stress, vascular dysfunction, and 
inflammation3-5. Additionally, defects in essential metabolic processes for energy supply and 
membrane function have been implicated in AD6,7.
The human brain is highly vulnerable to disturbances in energy metabolism, due to its relatively 
large energy consumption. Previous AD studies demonstrated alterations in global and cellular 
energy metabolism. FDG-PET studies have shown glucose hypometabolism in the retrosplenial 
cortex (RSC) and medial temporal lobe in people with mild cognitive impairment (MCI) and AD 
patients, as well as in cognitively normal carriers of the APOE ε4 allele8-11. Furthermore, the enzyme 
creatine kinase (CK), obtained from post-mortem AD tissue, shows reduced activity compared 
with samples that are free from neurological disease12,13. The CK reaction, key to balance brain 
energy metabolism, can quickly replenish ATP from the energy buffer phosphocreatine (PCr), 
when local energy demands suddenly increase14. This reaction also enhances the efficiency of 
mitochondrial oxidative phosphorylation (OXPHOS) by keeping adenosine diphosphate (ADP) 
sufficiently available 15 and prevents acidification by maintaining pH (for a review16). 
One of the earliest pathological changes in AD is synaptic dysfunction, which  correlates well with 
cognitive dysfunction and disease severity17. Alterations in neuronal membrane composition, vital 
for synaptic transmission, have been linked to synaptic dysfunction in AD18. For instance, post 
mortem studies found reduced levels of the major membrane components phosphatidylcholine, 
phosphatidylethanolamine and phosphatidylinositol7,19, as well as altered activity of catabolic 
and anabolic enzymes, suggesting  compensatory metabolic changes to reduce the rate of 
neuronal membrane loss20. 
High energy phosphates, such as ATP and PCr, and metabolites of phospholipid membrane 
metabolism can be assessed in vivo by phosphorus magnetic resonance spectroscopy (31P-MRS). 
This technique has been applied in AD e.g. 21,22-24, but previous studies, essentially focusing on 
single brain regions, were severely hampered by small sample sizes and low spectral resolution, 
resulting in a wide disparity in findings. Furthermore, differences in the control groups that were 
used, in the brain regions that were studied and in the disease stages and medication statuses 
of the patients, may have contributed to apparent inconsistencies in the literature. 
In the current study we tried to overcome these limitations, supported by recent technical advances. 
First, MRS imaging (MRSI) allows us to investigate multiple brain regions simultaneously. We 
specifically addressed regions that are of interest in AD, namely, the hippocampus, the RSC, and 
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the anterior cingulate cortex (ACC). Secondly, we utilized proton decoupling at 3T field strength, 
to increase spectral resolution and sensitivity. Finally, we selected a well-defined patient group 
and an age- and gender-matched control group. Accordingly, the purpose of our study was to 
assess phospholipid and energy metabolism in multiple brain regions in mild AD patients and 
healthy age-matched control subjects using 3D 31P MRSI. 
Materials and Methods 
Subjects and design
All visits of patients and controls to the Radboud university medical center (Nijmegen, the 
Netherlands) took place between 2012 and 2015. Patients aged ≥ 50 years with a diagnosis 
of possible or probable AD according to the revised National Institute of Neurological and 
Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders 
Association (NINCDS-ADRDA) 2011 criteria25 with evidence of the pathophysiological process 
(i.e. from structural MRI or cerebrospinal fluid biomarker assays)  and with a minimum Mini 
Mental State Examination (MMSE) score of 20 were recruited from the hospital’s memory clinic 
or by referral from regional hospitals. All AD patients participated in a randomized controlled trial 
on the effect of a medical food on brain phospholipid metabolism (Dutch Trial Register 3346). 
Only baseline data were used in the current study. Healthy control subjects, age- and gender-
matched to the AD group, were screened by telephone before being invited to the clinic. All 
subjects were drug-naïve for AD medication (cholinesterase inhibitors and NMDA-antagonists) 
and were free from neurological or psychiatric disorders (other than dementia, for the AD patients). 
Patients nor healthy controls used nutritional supplements containing docosahexaenoic acid, 
eicosapentaenoic acid or > 200% of the recommended daily allowance of vitamins B, C, or E. 
All subjects were screened for MRI contra-indications before inclusion in the study.
Written informed consent was obtained from all subjects and from the informal caregivers of the 
AD patients. The local ethics committee reviewed and approved the protocol and the study was 
conducted in accordance with the Declaration of Helsinki. 
Medical history, medication use and MMSE were recorded from all subjects, as well as date 
of birth, sex, ethnicity, smoking habits, alcohol consumption, and family history of AD. Level of 
education was classified according to Verhage26 (comparable with the International Standard 
Classification of Education) and categorized in three groups: primary education or lower (low), 
junior vocational training (middle), and senior vocational or academic training (high).
MR acquisition
MRI and MRS were performed on a Magnetom Tim Trio 3T MR system (Siemens, Erlangen, 
Germany) with a dual-tuned 1H/31P volume head coil (Rapid Biomedical, Wuerzburg, Germany). 
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High resolution MR images were acquired with a T1-weighted magnetisation-prepared rapid 
gradient-echo sequence (TR=2300 ms, TE=3.16 ms, 15° flip-angle, 176 sagittal slices, slice-
matrix size=256×256 mm, slice thickness=1 mm, voxel-size=1×1×1 mm, TA=6:25 min).
31P-MR spectra were acquired with whole brain 3D MRSI (TR=2000 ms, acquisition delay=0.10 
ms, 40° flip-angle, WALTZ4 proton decoupling at 50% of 512 ms acquisition duration, FOV 
260x260x260 mm; matrix size=10x10x10, acquisition time 13:08 min). K-space was sampled 
with a weighted elliptical phase encoding scheme with four averages. The volume of interest 
was centered on the midline and parallel to the line from the anterior commissure to the posterior 
commissure. Spatial post-processing consisted of zerofilling to a matrix size of 16x16x16. The 
nominal volume of the measured voxels is about 17.5 cc, the effective voxel at 64% of the spatial 
response function has a spherical shape with a volume of about 40 cc27. 
 
MRS and MRI data analyses
Four regions of interest (ROI) were selected for analysis from the 3D 31P-MRSI data: ACC, RSC, 
and left and right hippocampus (HL and HR). Guided by the T1-weighted images, the MRSI 
grid was shifted in the x, y and z dimension to position voxels in the ROI’s (Figure 1). For the 
anterior cingulate cortex (ACC), a voxel was selected anterior to the genu of the corpus callosum, 
with the inferior border aligned with the the line from the anterior commissure to the posterior 
commissure (AC-PC line), and on the midsagittal plane. For the retrosplenial cortex (RSC), a 
voxel on the midsagittal plane was selected posterior to the splenium of the corpus callosum, 
with the inferior border aligned with the AC-PC line. For left and right hippocampus (HL and HR), 
a voxel was selected at the anterior end of each hippocampus, with the inferior and lateral border 
of the voxel aligned with the inferior and lateral side of the hippocampus. 
The software package Metabolite Report (Siemens Healthcare, Erlangen, Germany) was used for 
post-processing (i.e. 100 ms exponential filter, zero-filling, phase correction, baseline correction) 
and for automatic fitting of the spectra in the time-domain using prior knowledge appropriate 
for 31P MR spectra (own spectral data and de Graaf28). Eleven well-resolved resonance peaks 
were fitted: the phospholipid metabolites phosphoethanolamine (PEth), phosphocholine (PCh), 
glycerophosphoethanolamine (GPEth) and glycerophosphocholine (GPCh), the high-energy 
phosphorus molecules PCr, ATP (α-ATP, β-ATP and γ-ATP), nicotinamide adenine dinucleotide 
(NAD(H)) and inorganic phosphate (Pi), and membrane-bound phospholipid. In this procedure, 
PCh (6.7 ppm; bounds 6.6-7.5 ppm), PEth (6.3 ppm; bounds 6-6.55 ppm), GPCh (3 ppm; 
bounds 2.8-3.2 ppm), GPEth (3.6 ppm; bounds 3.2-3.8 ppm), PCr (0 ppm; bounds -0.5-0.5 
ppm), and inorganic phosphate (Pi) (4.8 ppm; bounds 4.5-5.7 ppm) were each modeled as a 
single Gaussian peak (default line width of 15 Hz, variable between 1 and 60 Hz). PCh, PEth 
and Pi were constrained to the same line width, and GPCh and GPEth were constrained to the 
same line width. Membrane phospholipids (MP) (2.25 ppm, bounds 2-2.4 ppm) were fitted with 
a single Gaussian peak, with a line width of 65 Hz (variable between 30 and 80 Hz). The γ and 
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α resonances of adenosine-5'-triphosphate (ATP) were each fitted as a doublet with two single 
Gaussian peaks with a constrained separation according to their J-coupling constants (γATP 
-2.5 ppm, -0.28; bounds -3--2 ppm; αATP -7.5 ppm, -0.327; bounds -9--7 ppm) 28, and forced 
equal amplitude. The single peaks were constrained to the same line widths (default 15 Hz, 
variable between 5 and 80 Hz). The β resonance of ATP was fitted as a triplet with three single 
Gaussian peaks with a constrained separation according to the J-coupling constant ( -16.3 ppm 
+/- 0.325; bounds -18--14 ppm)28. The two outer peaks were forced to an amplitude equal to 
half the intensity of the middle peak. Line width was constrained to the line width of the other 
ATPs. NAD(H) (-8.3 ppm; bounds -9.5--7.5 ppm) was modeled as a single Gaussian peak with 
line width constrained to the line width of ATP.
Both a quantitative evaluation of the fitting results and a visual quality control were performed. 
Quantitatively, only metabolite fits with a Cramer–Rao lower bound of ≤30% were considered 
reliable. Qualitatively, two spectroscopists independently checked the spectra by visual 
inspection of the original spectra and the fitting results. If a metabolite peak was visually present, 
and its fit was assigned to the correct resonance—giving a minimal residue in the subtraction 
spectrum—the fitting result was accepted. 
 
Figure 1 
Voxel selection of 31P MR spectra displayed on sagittal (left) and coronal (right) anatomical images: anterior 
cingulate cortex (blue), retrosplenial cortex (yellow), left and right hippocampus (purple). The nominal voxel 
size is indicated by squares and the approximation of the effective spherical voxel size is indicated by circles. 
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The integral of each metabolite resonance was expressed as a percent area of the total 
phosphorous signal. Hereby, the data were corrected for CSF content and thus for differences 
in atrophy. Phosphomonoesters (PME) were calculated from the sum of PEth and PCh, 
phosphodiesters (PDE) from GPEth and GPCh and total ATP (tATP) from the sum of α-ATP, 
β-ATP and γ-ATP. In addition, the ratios PME/PDE, PE/GPE, PC/GPC and PCr/Pi were computed. 
Intracellular pH was determined from the chemical shift difference between the PCr and Pi 
resonance peaks29.
The T1-weighted images were segmented into grey matter (GM), white matter (WM) and CSF 
using automatic segmentation software (SPM8, Welcome Trust Centre for Neuroimaging, 
London, UK; VBM8, Structural Brain Mapping Group, Jena, USA). Binary tissue maps (matrices) 
of GM, WM, CSF were convolved with the, digitally sampled, mathematically-modelled three 
dimensional point-spread function of the MRSI, using Matlab 2012b (The Mathworks, Inc., 
Matrick, MA), to obtain theoretically correct values of the contribution of tissue type to each ROI 
(each consisting of one MRS voxel). GM-to-WM ratio (GM/WM) was calculated for each ROI for 
each subject. 
Statistical analyses
Two-factorial mixed ANOVAs were used to test differences in tissue content (GM, WM, and CSF) 
and GM/WM in each ROI between mild AD patients and controls. Group and brain region (ROI) 
differences were analyzed for each spectroscopy outcome parameter using a mixed model 
with group (AD or control), sex, brain region and its interaction with group as fixed factors, 
considering brain region as a within subject factor, and adjusting for age. An unstructured 
variance-covariance matrix for brain region was selected.  The group-by-brain region interaction 
was only kept in the model if p<0.10. In the covariate analysis, GM/WM in each ROI was added 
to the final primary model of each parameter, to investigate the effect of tissue composition on 
the effects of group and brain region. Although the inclusion of GM/WM in the final model led 
to a small change (10-20 %) in many parameter estimates, this was mainly without a change in 
main and/or interaction effects. Therefore we report the primary model in tables and figures and 
refer to the effect of GM/WM only where it led to a change in the main and/or interaction effects, 
and with > 20% change in the parameter estimates of group or brain region. Goodness of fit was 
assessed by comparing Bayesian Information Criteria (BIC) and homoscedasticity and normality 
of residuals were assessed by visual inspection. Statistical analyses were performed using SAS 
9.2 Software for Windows (SAS Institute Inc., Cary, NC, USAf). Statistical significance was set at 
p < 0.05 without correction for multiple testing.
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Results 
Subjects 
A total of 33 mild AD patients and 35 healthy control subjects were enrolled in the study and 
subjected to MRI and MRS measurements. Two AD patients had MR spectra of low quality (due 
to severe motion and a dental implant) and four control subjects were found to meet an exclusion 
criterion during or after the visit (two subjects took nutritional supplements, two subjects had 
incidental findings indicating neurological disease). Therefore, 31 AD patients and 31 controls 
were included in the final analysis. The groups were similar with respect to age and gender (see 
Table 1 for subject characteristics). 
Table 1 Subject characteristics
Alzheimer’s disease
n=31
Healthy controls
n=31
Age 73.4 years (6.8) 73.5 years (6.3)
Gender (%) 13 males (42%) 15 males (48%)
MMSE 23.2 (2.0) 28.1 (1.4)
Time since AD diagnosis 1.6 months [0.2-15.3] -
BMI 25.4 kg/m2 (3.8) 26.3 kg/m2 (4.5)
Educational level (low/middle/high) 9/16/6 4/9/18
Smoking (never/past/current) 13/17/1 6/22/3
≥ 1 relatives with AD (n) 19 7
MMSE, mini mental state examination; AD, Alzheimer’s disease; BMI, body mass index. Data are presented 
as mean (standard deviation) or median [range] unless otherwise indicated. 
ROI tissue contribution 
The interaction between group and brain region for GM and CSF contributions to the total 
volume of each ROI was not significant, but GM and CSF differed significantly between groups, 
and between brain regions (all p<0.001). GM was lower and CSF was higher in AD patients 
than in healthy control subjects  (mean % ± SD, GM:36.3±4.7 vs. 40.5±4.0; CSF: 22.5±4.7 vs. 
18.1±3.5). overall, GM was highest in the right hippocampus, followed by left hippocampus, and 
then followed by equal amounts in RSC and ACC (data not shown). CSF in RSC and ACC was 
higher than in both hippocampi. There was a significant interaction between group and brain 
region for WM (p=0.004) and GM/WM (p=0.021). WM was higher in AD patients compared with 
controls in the right hippocampus (41.5±3.0 vs. 40.0±2.6), but not in the other brain regions. 
GM/WM was lower in AD patients than in controls in ACC, and both hippocampi, but not in RSC 
(data not shown). 
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MRS results
High quality spectra were obtained with well-resolved phosphomonoester and phosphodiester 
signals (Figure 2). We did not observe a difference in the linewidth of PCr between AD and 
controls (mean±SD 11.5±3.9 Hz and 11.1±3.0 Hz, not tested). ROI tissue contributions showed 
typical differences with lower GM and higher CSF in AD patients compared with controls.  
In the statistical analysis, the interaction between group and brain region was kept in the model 
for PCr, γATP and βATP, because it survived our criterion of p<0.10. For all other outcome 
parameters, the interaction term had a p-value >0.10 and was removed from the model. 
Figure 2 
Representative spectrum from the retrosplenial cortex of an Alzheimer’s disease patient (73 years old). 
Zero filling to 4096 data points and an 8Hz Gaussian filter were applied. PEth, phosphoethanolamine; 
PCh, phosphocholine; Pi, inorganic phosphate; GPEth, glycerophosphoethanolamine; GPCh, 
glycerophosphocholine; MP, membrane phospholipids; PCr, Phosphocreatine; ATP, adenosine triphosphate; 
NAD(H), nicotinamide adenine dinucleotide; ppm, parts per million
Differences in energy metabolites and pH between groups
A significant interaction between group and brain region was found for PCr, showing that 
normalized PCr signals were higher in mild AD patients compared with healthy control subjects 
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in the RSC (Least Square (LS) mean difference=0.86, SEM=0.29, p=0.004), HL (LS mean 
difference=1.52, SEM=0.52, p=0.005) and HR (LS mean difference=1.47, SEM=0.38, 
p<0.001), but not in the ACC (p=0.947) (Figure 3A). The interaction between group and brain 
region was not significant for γATP and βATP. A main effect of group was found for PCr/Pi, 
showing that this ratio was higher in mild AD patients compared with healthy controls (LS mean 
difference=0.22, SEM=0.11, p=0.046) (Figure 3B). Also pH was increased in AD patients 
compared with controls (LS mean difference=0.008, SEM=0.004, p=0.032) (Figure 3C). No 
group differences were found for γATP, βATP, αATP, total ATP, Pi, and NAD(H) (all p>0.05). For a 
summary of group effects see Table 2. 
Differences in phospholipid metabolites between groups
No interaction or group difference between mild AD patients and healthy control subjects were 
found for any of the phospholipid metabolites (PEth, PCh, GPEtn, GPCh, PME, and PDE; Table 
2) or their ratios (PEth/GPEth, PCh/GPCh, and PME/PDE) (all p>0.05). 
Differences in phosphorus metabolites and pH between brain regions 
Brain region significantly affected all outcome parameters (all p<0.05), except PCh and PME 
(p>0.05). The normalized signals of total ATP, αATP, βATP, γATP, NAD(H), PEth, GPEtn, GPCh, 
and PDE were lower in the RSC than in the ACC and both hippocampi (all p<0.05), while the 
pattern was reversed for the ratios PCh/GPCh and PME/PDE (p<0.001). We found no difference 
between the left and right hippocampus for any of the energy and phospholipid metabolites or 
pH (p>0.05), except for αATP (LS mean difference=0.65, SEM=0.26, p=0.015). See Table 3 for 
an overview of the differences between brain regions.
Influence of tissue content
In the covariate analysis GM/WM was added to the final model. This did not change the effects 
of group, brain region or the  interaction between group and brain region on PCr, Pi, total ATP, 
αATP, βATP, γATP, NAD(H), pH or any of the phospholipid metabolite signals. However, for PCr/Pi 
the main effect of brain region was reduced to a trend (p=0.062) and the parameter estimates 
changed substantially, when GM/WM was included in the model. There was no change in the 
effect of group on PCr/Pi. 
Discussion 
In this study we obtained high-quality 31P-MRS data in a large group of mild AD patients and 
in a well-matched healthy elderly population. High spectral resolution enabled us to gather 
information on high-energy phosphates, as well as on specific phospholipid metabolites. 
Measurements were performed in multiple brain regions that are among the most investigated in 
AD and for the first time, these areas were investigated simultaneously by 31P-MRS. We detected
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Figure 3 
Normalized phosphocreatine (PCr; A), ratio of PCr to inorganic phosphate (PCr/Pi; B) and pH (C) in patients 
with Alzheimer’s disease (AD) and healthy control (HC) subjects. Data represent Least Square means±SEM, 
*p<0.05 AD vs HC. ACC, anterior cingulate cortex; RSC, retrosplenial cortex; HL, left hippocampus; HR, 
right hippocampus. 
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Table 2 Main effect of group (healthy controls vs Alzheimer’s disease) on phosphorus metabolite signals 
and tissue pH for all investigated regions
AD Control p-value
PCr* 19.04±0.18
n=124
18.08±0.18
n=124
<0.001
Pi 5.30±0.11
n=121
5.47±0.11
n=123
0.240
PCr/Pi 3.71±0.09
n=121
3.49±0.09
n=123
0.046
total ATP 42.88±0.27
n=124
43.17±0.27
n=124
0.445
NAD(H) 3.96±0.11
n=103
4.09±0.11
n=96
0.388
PEth 8.19±0.11
n=119
8.33±0.11
n=122
0.375
PCh 3.90±0.07
n=112
3.93±0.07
n=114
0.757
GPEth 4.32±0.11
n=109
4.31±0.11
n=117
0.942
GPCh 5.96±0.15
n=108
6.08±0.15
n=109
0.526
pH 7.037±0.003
n=121
7.028±0.003
n=123
0.032
LS means ± SEM of metabolite levels, as percentage of total phosphorus signal, in patients with Alzheimer’s 
disease and healthy control subjects. Significant group effects (p<0.05, AD versus Control) indicated in 
bold. *PCr also has a significant interaction between group and brain region. LS, least squares; SEM, 
standard error of the mean; n, number of observations; AD, Alzheimer’s disease; HC, healthy control; PCr, 
Phosphocreatine; Pi, inorganic phosphate; ATP, adenosine triphosphate; NAD(H), nicotinamide adenine 
dinucleotide; PEth, phosphoethanolamine; PCh, phosphocholine; GPEth, glycerophosphoethanolamine; 
GPCh, glycerophosphocholine
increased phosphocreatine and pH, but no changes in phospholipid metabolite signals in mild 
AD patients. Interestingly, the increase in PCr was observed in the RSC and in the hippocampi, 
regions that both show early pathological changes in AD, but not in the ACC, a region known 
to be involved in the disease at a later stage. This suggests that the PCr abnormality expands 
across brain regions in a similar fashion as other AD pathologies, such as tau2. Furthermore, in 
both groups pH, high energy phosphates, and most phospholipid metabolites differed across 
brain regions.
As in vivo human 31P MRS brain studies are nearly always performed under signal saturating 
conditions, changes in T1 relaxation time may affect metabolite signal intensities30. Although 
we cannot exclude that such an effect has contributed to the increased PCr signal, it requires
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Table 3 Main effect of brain region on phosphorus signal integrals and tissue pH
ACC RSC HL HR p-value
PCr* 17.75±0.18†,‡,§
n=62
19.16±0.14¶
n=62
18.47±0.26
n=62
18.87±0.19
n=62
<.001
Pi 5.34±0.12
n=61
5.65±0.10¶
n=62
5.21±0.16
n=61
5.34±0.18
n=60
0.027
PCr/Pi 3.42±0.09‡,§
n=61
3.46±0.07¶,#
n=62
3.76±0.14
n=61
3.76±0.12
n=60
0.009
total ATP 42.58±0.38†,‡,§
n=62
40.06±0.33¶,#
n=62
45.24±0.38
n=62
44.21±0.41
n=62
<.001
NAD(H) 4.39±0.12†
n=49
3.47±0.11¶,#
n=61
4.17±0.16
n=45
4.08±0.14
n=44
<.001
PEth 8.45±0.18†
n=61
7.81±0.12¶,#
n=62
8.31±0.15
n=60
8.46±0.18
n=58
<.001
PCh 3.99±0.10
n=55
3.96±0.10
n=61
3.94±0.09
n=56
3.76±0.11
n=54
0.429
GPEth 4.76±0.15†,,§
n=51
3.72±0.09¶,#
n=61
4.42±0.13
n=57
4.36±0.11
n=57
<.001
GPCh 6.69±0.26†
n=46
5.01±0.12¶,#
n=61
6.11±0.15
n=56
6.28±0.16
n=54
<.001
pH 7.023±0.004‡,§
n=61
7.017±0.002¶,#
n=62
7.039±0.004
n=61
7.050±0.005
n=60
<.001
LS means ± SEM of metabolite levels, as percentage of total phosphorus signal, in anterior cingulate cortex, 
retrosplenial cortex and hippocampi. Significant (p<0.05) main effect of brain region indicated in bold. *PCr 
also has a significant interaction between group and brain region. p<0.05, ACC vs †RSC, ‡HL, or §HR; 
RSC vs ¶HL, or #HR. LS, least squares; SEM, standard error of the mean; n, number of observations; ACC, 
anterior cingulate cortex; RSC, retrosplenial cortex; HL, left hippocampus; HR, right hippocampus; PCr, 
Phosphocreatine; Pi, inorganic phosphate; ATP, adenosine triphosphate; NAD(H), nicotinamide adenine 
dinucleotide; PEth, phosphoethanolamine; PCh, phosphocholine; GPEth, glycerophosphoethanolamine; 
GPCh, glycerophosphocholine. 
a rather drastic decrease in PCr’s T1 value from about 3 to 2 seconds. Moreover, no increases 
in PME and PDE signals were detected, while those would be affected more severely by a T1 
decrease31. A potential cause for relaxation enhancement is a higher brain iron accumulation 
in AD patients32, but this would increase the signal linewidth, which was not observed. Thus, 
the most likely explanation for the increased PCr signal is a higher tissue concentration of this 
compound.
Elevated PCr signals have been reported before for AD patients in comparison with young 
controls23, but as PCr also increases with age in healthy persons30,33,34 it is unclear whether this 
finding was due to an aging effect. The current results showed increased PCr, and PCr/Pi, in AD 
patients compared with elderly controls. In contrast, two earlier studies showed a decrease in
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prefrontal PCr in mild, but not severe, AD24 and decreased PCr/Pi in the frontal lobe21. However, 
these studies were performed at 1.5T with only surface coil localization and involved small 
sample sizes.
As the concentration of high energy phosphates depends on the balance between energy 
production and energy utilization, increases in steady state PCr levels and PCr/Pi reflect a 
redistribution in the content of metabolites involved in the connected CK and ATPase pseudo-
equilibria35. This may be the consequence of reduced utilization of ATP33, caused by synaptic 
dysfunction or loss of other energy requiring functionalities36,37. Although these changes are 
expected to lower ATP production and thus PCr, the final balance between reduced energy 
production and consumption may still result in a higher PCr level. To maintain equilibrium, the 
increased PCr should be accompanied by changes in the levels of other substrates of the CK 
reaction, such as a higher ATP concentration. Previous studies reported an increase in (γ)
ATP23,24,38, although no alterations in ATP levels were found in the current nor in several other 
studies e.g. 21,22,39. Alternatively, a higher PCr may result from an increased total amount of cellular 
creatine (Cr). However, in vivo measurement of total Cr content in MCI and AD patients provide 
no clear evidence that Cr is increased in the disease40,41. Finally, decreases in ADP and/or H+ 
concentration may accompany the PCr increase. Indeed, a slight increase in pH was detected 
in mild AD patients, but it does not fully compensate for the increase in PCr when equilibrium is 
assumed. Changes in PCr levels have also been associated with decreased CK activity in the 
AD brain23,33. However, it is unlikely to be a direct effect of this decrease as even in cytosolic CK 
knockout mice the remaining CK activity (< 20%) is sufficient to preserve equilibrium42. Clearly, a 
strongly affected reaction rate will affect processes that require rapid (local) energy supply, and 
a higher PCr level may be a flux adaptation to this condition.    
There is some evidence for involvement of PCr in processes beyond the PCr-CK system. 
Since glutamate uptake by synaptic vesicles is stimulated by PCr, independent of ATP or 
CK43,  increased PCr may prevent glutamate excitotoxicity44. Furthermore, PCr may be able 
to bind to and stabilize phospholipid membranes45 and may function as an osmolyte46 and a 
neurotransmitter47. In addition, differences in metabolite levels may be explained by variations 
in tissue and cell type48,49, although our results remained unchanged when adjusting for grey 
and white matter. A prominent neuropathological feature in AD is astrogliosis50. As this alters the 
neuron-to-glia ratio within grey and white matter51, it is possible that morphological differences 
between AD patients and healthy aged controls play a role in the alterations in PCr and pH.  
Contrary to our expectation, we have not observed differences between mild AD patients and 
controls in any of the phospholipid metabolites, although preclinical and post-mortem studies 
show alterations in membrane function and lipid composition in AD7,20. No previous in vivo 
studies have reported on PEth, PCh, GPEth or GPCh, but several studies reported changes 
of their total amounts, i.e.  PME, PDE or their ratio, in AD38,39,52, although others reported no 
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differences in these metabolites 21,53-55. The most consistent finding seems to be an increase 
in total PME in the prefrontal cortex in AD compared with elderly controls24,52,56. In the present 
study, part of the frontal cortex was covered in the ACC measurement, but we did not find 
changes in PEth, PCh, nor total PME. However, changes in the complex phospholipid cycle may 
be too small at this disease stage to be detected with the current methodology. Although we had 
sufficient spectral resolution to resolve the phosphomonoester signal of PEth and PCh, and the 
phosphodiesters signal of GPEth and GPCh, these may still reflect metabolites connected to 
different phospholipid pools. Moreover, differential expression of phosphatidylethanolamine and 
phosphatidylcholine species across hippocampal subfields was recently shown in AD57. 
MRSI revealed that high energy phosphates, pH and most phospholipid metabolites vary 
extensively across brain regions that are of interest in AD. These differences existed in both mild 
AD patients and controls, and were not explained by regional variation in grey and white matter 
content, with the ratio PCr/Pi as the sole exception. This indicates that the investigated regions 
are metabolically different from each other. It also underlines that regional differences should be 
taken into account in any cross-sectional or longitudinal metabolic study. Moreover, as shown 
here for PCr, changes in metabolite levels in disease may not be the same for all brain regions.  
The current study only reports on relative metabolite levels, as obtaining absolute quantifications 
requires several assumptions, which adds complexity and reduces reliability. Moreover, when 
the variation in atrophy between and within groups is large, relative measurements are preferred 
over absolute. In future studies it would be valuable to include preclinical AD patients or an 
at-risk population to clarify the disease stage in which abnormalities in PCr and pH appear. In 
addition, magnetization transfer experiments to determine the CK and ATPase reaction rates with 
measurements of absolute concentrations of PCr and ATP to determine fluxes35, would elucidate 
whether the dynamics of the  PCr-CK and ATPases systems are affected in AD.
Conclusion 
To the best of our knowledge, this is the largest study to date investigating brain phospholipid 
and energy metabolism in AD by 31P MRS. Increased PCr levels were found in regions that show 
early degeneration in AD, but not in the ACC, a region known to be involved in this disease at 
a later stage. Together with an increased pH, this indicates that energy metabolism is altered 
in mild AD. Although most phospholipid metabolites, like the high energy phosphates, differed 
between the investigated brain regions in both groups, no alterations in phospholipid metabolism 
were found specific to mild AD. 
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Abstract 
INTRODUCTION: Synaptic dysfunction contributes to cognitive impairment in Alzheimer’s 
disease (AD) and may be countered by increased intake of nutrients that target brain phospholipid 
metabolism. This study explores whether the medical food Souvenaid affects brain phospholipid 
metabolism in AD patients. METHODS: 34 drug-naïve mild AD patients (MMSE≥20) were 
enrolled in this exploratory double-blind randomized controlled study. Before and after 4 weeks 
intervention with Souvenaid or control product, phosphorus and proton magnetic resonance 
spectroscopy (MRS) assessed surrogate measures of phospholipid synthesis and breakdown 
(phosphomonoesters [PME] and phosphodiesters [PDE]), neural integrity (N-acetyl aspartate), 
gliosis (myo-Inositol) and choline metabolism (choline-containing compounds [tCho]). 
RESULTS: MRS data from 33 patients were analyzed. PME/PDE and tCho were higher after 4 
weeks of Souvenaid compared with control. No differences were observed in the other MRS 
outcome parameters.  DISCUSSION: Phosphorus MRS reveals that Souvenaid affects brain 
phospholipid metabolism in mild AD, in line with findings from preclinical studies. 
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Introduction 
Synaptic dysfunction is a major contributing factor to cognitive impairment in Alzheimer’s disease 
(AD)1,2 and may be caused by deficits in neuronal membrane composition and function3,4. As 
the neuronal membrane is mainly composed of phospholipids5, interventions that target brain 
phospholipid metabolism may affect cognitive function in AD. 
The most abundant phospholipids in the neuronal membrane are phosphatidylethanolamine (PE) 
and phosphatidylcholine (PC)4,5. They are formed in the Kennedy cycle, wherein phosphomonoesters 
(PME) are converted to phospholipids that can then be incorporated in neuronal membranes6. The 
breakdown of these phospholipids releases phosphodiesters (PDE), that can either be used for 
resynthesis or be further broken down7. The synthesis of brain phospholipids is influenced by the 
availability of specific nutrients, consisting of rate-limiting phospholipid precursors, to the brain8,9. 
This is not only affected by nutritional intake, but also by the intake of cofactors that influence 
precursor uptake and metabolism. Increasing the availability of several precursors proved to have 
a synergistic effect on phospholipid formation as well as on dendritic spine density9-12. Furthermore, 
circulating levels of most of these nutrients (precursors and cofactors) as well as brain choline levels 
are lower in patients with AD13-15, thus lowering precursor availability. The specific multi-nutrient 
combination Fortasyn® Connect (FC) in the medical food Souvenaid® contains precursors and 
cofactors in the phospholipid synthesis pathway (docosahexaenoic acid [DHA], eicosapentaenoic 
acid [EPA], uridine monophosphate [UMP], choline, phospholipids, selenium, folic acid, and 
vitamins B6, B12, C and E), and has been formulated to promote neuronal membrane (phospholipid) 
formation and function in AD8. Previous studies in animal models of AD and aging have shown 
that long term supplementation with FC positively affects explorative behavior and memory16,17, 
in addition to enhancing phospholipid synthesis and improving cholinergic transmission18. This 
indicates that supporting synaptic function by increasing phospholipid formation is a promising 
strategy to improve cognition or reduce cognitive decline. 
Randomized controlled trials in patients with AD demonstrated improvement in memory 
performance in mild AD over 12-24 weeks intervention with this specific multi-nutrient 
combination19-21 as well as altered functional connectivity and brain network organization22. 
However, the physiological underpinnings in humans remain to be further elucidated.
Neither synapse number nor phospholipid membrane composition can be assessed directly in 
vivo, but phosphorus magnetic resonance spectroscopy (31P-MRS) allows for the non-invasive 
investigation of phospholipid building blocks and breakdown products, i.e. PME and PDE, 
respectively23. In addition, using proton (1H) MRS, brain metabolites related to neural integrity 
(N-acetyl-aspartate [NAA]), gliosis (myo-inositol [mI]), choline metabolism (total choline [tCho]) 
and energy metabolism (total creatine [tCr]) can be assessed as well23,24. Hence, the current 
study explores whether  the medical food Souvenaid affects brain phospholipid metabolism and 
neural integrity in patients with mild AD using 31P and 1H-MRS. 
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Methods 
Subjects and design
All visits took place between October 2012 and February 2015 at the Radboud university medical 
center (Nijmegen, the Netherlands). AD drug-naïve patients aged ≥ 50 years with a diagnosis of 
probable or possible AD, and a minimum Mini Mental State Examination (MMSE) score of 20, 
were recruited from the hospital’s memory clinic or by referral from regional hospitals. All subjects 
were screened for magnetic resonance imaging (MRI) contra-indications before inclusion in the 
study. Written informed consent was obtained from all patients and their informal caregivers. 
The local ethics committee reviewed and approved the protocol. The study was conducted in 
accordance with the Declaration of Helsinki and registered in the Dutch Trial Register (NTR3346). 
Eligible subjects were randomly allocated to receive either the test product (i.e. Souvenaid, 
containing the specific nutrient combination FC) or an iso-caloric control product once daily as a 
drink for a double-blind period of 4 weeks (1:1 randomization, stratified based on gender). The 
test product contained DHA, EPA, phospholipids, choline, UMP, selenium, folic acid and vitamins 
B6, B12, C and E (Supplementary Table A.1). 
At baseline and after 4 weeks, venous blood samples were taken and MR measurements were 
performed. MR measurements at week 4 took place at least two hours after intake of the last 
study product. For the purpose of compliance and safety, a phone call was conducted after 14 
days of product intake. A final follow-up call was conducted 2 weeks after the last visit. More 
details on subjects, study design, biochemical analyses of blood samples, the MR protocol and 
MR analyses can be found in the Supplementary Material.
MR protocol
MRI and MRS were performed on a Magnetom Tim Trio 3T MR system (Siemens, Erlangen, 
Germany) with a dual-tuned 1H/31P volume head coil (Rapid Biomedical, Wuerzburg, Germany). 
High resolution MR images were acquired with a T1-weighted magnetisation-prepared rapid 
gradient-echo sequence. 31P-MR spectra were acquired with a whole brain 3D MR spectroscopic 
imaging (MRSI) pulse-acquire sequence. 1H-MR spectra were acquired with a single slice 2D 
semi Localization by Adiabatic Selective Refocusing MRSI sequence (covering the hippocampi) 
or a single voxel point resolved spectroscopy sequence (anterior and posterior cingulate cortex 
[ACC and PCC]). 
MR data analysis
Four regions of interest (ROI) were selected for analysis from the 3D 31P-MRSI data: ACC, 
retrosplenial cortex (RSC), and left and right hippocampus (HL and HR). From the 2D 1H-MRSI 
data, two voxels from the hippocampi (HL and HR, respectively) were selected for analysis, in 
addition to the single voxel data from the ACC and PCC (Figure 1AC).
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The software packages Metabolite Report (Siemens Healthcare, Erlangen, Germany) and 
LCModel (Version 6.3-0C25) were used for post-processing and automatic fitting of 31P-MR and 
1H-MR spectra, respectively. Both a quantitative evaluation of the fitting results and a visual 
quality control were performed. 
The intensity of each phosphorus metabolite resonance was expressed as a percentage area 
of the total phosphorous signal area. PME was calculated as the sum of phosphoethanolamine 
(PEth) and phosphocholine (PCh), PDE as the sum of glycerophosphoethanolamine (GPEth) and 
glycerophosphocholine (GPCh), and total adenosine triphosphate (tATP) as the sum of α-ATP, 
β-ATP and γ-ATP. In addition, the ratios PME/PDE, PEth/GPEth, PCh/GPCh and phosphocreatine/
inorganic phosphate (PCr/Pi) were computed. 
Regarding 1H-MRS, the intensities of N-acetylaspartate (NAA), myo-inositol and glycine (mI), and 
choline-containing compounds (total choline, tCho: PCh, GPCh and free choline) were expressed 
relative to the intensity of creatine and phosphocreatine (total creatine, tCr). Additionally, water-
referenced levels of NAA, mI, tCho and tCr were expressed in mM, and the ratio of NAA to mI 
(NAA/mI) was calculated. 
Statistical analyses
All statistical analyses were performed for the modified intention to treat (ITT) data set, 
including all subjects who received at least one unit of the study product and with at least one 
MR measurement. The main statistical analyses of the MRS outcome parameters were also 
performed for the per protocol (PP) population, which includes all subjects who had no major 
protocol deviations.
All blood outcome parameters at week 4 were analyzed using analyses of covariance (ANCOVA) 
with between-subjects factors intervention group and gender, and baseline measure as covariate. 
All MRS outcome parameters at week 4 were analyzed using a predefined multilevel model 
with intervention group (test or control), gender, brain region and its interaction with intervention 
group as fixed factors, considering brain region as a within subject factor, and adjusting for 
baseline. The analyses were conducted (a) using the observed baseline as covariate (missing 
baseline values were set to missing, ‘main model – observed’) and (b) using the imputed baseline 
values (missing baseline values were replaced by imputed baseline values) as covariate (‘main 
model – with imputation’). Imputation of the baseline value was performed by a regression 
imputation using age, gender, and brain region. An unstructured variance-covariance matrix 
for brain region was selected. If the p-value for intervention group by brain region interaction 
was <0.10 ANCOVA models per brain region were conducted. If the p-value for the intervention 
by brain region interaction was > 0.10, the interaction term was dropped from the model. 
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Figure 1 
Voxel selection and representative examples of 31P and 1H MR spectra. A, voxel selection of 31P MR spectra 
displayed on sagittal (left) and coronal (right) anatomical images: anterior cingulate cortex (blue), retrosplenial 
cortex (yellow), left and right hippocampus (purple). The nominal voxel size is indicated by squares and the 
approximation of the effective spherical voxel size is indicated by circles. B, representative 31P MR spectrum 
from the RSC. Zero fi lling to 4096 data points and an 8 Hz Gaussian fi lter were applied. C, sagittal (left) 
and transversal (right) anatomical images showing single voxel volumina of 1H MR spectra in anterior 
cingulate cortex (blue), posterior cingulate cortex (yellow), and voxel selection of left and right hippocampus 
(purple). D, representative 1H MR spectrum from the PCC. Zero fi lling to 8192 data points and an 2 Hz 
Lorentzian fi lter were applied. PEth, phosphoethanolamine; PCh, phosphocholine; Pi, inorganic phosphate; 
GPEth, glycerophosphoethanolamine; GPCh, glycerophosphocholine; MP, membrane phospholipids; PCr, 
Phosphocreatine; ATP, adenosine triphosphate; NAD(H), nicotinamide adenine dinucleotide; ppm, parts per 
million; NAA, N-acetyl-aspartate; tCho, Choline-containing compounds; tCr, total Creatine; mI, myo-inositol.
Predefi ned supportive analyses involved linear mixed model analyses including the baseline 
value of the outcome parameter in the outcome vector and including intervention group, gender, 
time, brain region and 2-way and 3-way interactions between intervention group, brain region, 
and time as fi xed factors, and a random intercept for time per subject. In this supportive model, 
the intervention effect is expressed by the interaction of time by intervention group.  Additionally, 
the primary model analyses were repeated (a) with adjustments for pre-specifi ed possible 
confounders (i.e., MMSE, education level [low, medium, high], gray matter fraction [GMf], and 
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intake of choline containing food [only for choline related outcome parameters]), and (b) for 
the one brain region for which most data was available. For all fitted models, the influence 
diagnostics were used to explore the influence of different observations on the models. 
The supportive and covariate analyses were conducted only for the main 31P-MRS (PME, PDE, 
PME/PDE) and main 1H-MRS outcomes (NAA/tCr, mI/tCr, Cho/tCr, NAA/mI). Analyses of these 
main outcome parameters were performed on partially unblinded data (using intervention group 
coded as X and Y), allowing analysis of the intervention effect while keeping the statisticians 
blinded to group allocation. Statistical analyses were performed by both AR and AY using SAS 
9.2 and SAS 9.4, respectively (SAS Institute Inc., Cary, NC, USA). Statistical significance for the 
intervention effect was set at p < 0.05 without correction for multiple testing. 
Results
Subjects
Of the 40 subjects who were screened, 34 subjects were included and randomized to receive 
either the test or the control product. One subject dropped out from the study without MR 
measurements and prior to product dispense, due to unexpected claustrophobia which was an 
exclusion criteria for the current study as described in the study protocol. Hence, 33 subjects 
were included in the modified ITT population. Major protocol deviations were present in four 
subjects: no MR measurements at week 4 (n=2) or (suspected) double product intake prior 
to week 4 measurements (n=2). Hence, 29 subjects were included in the PP population (for a 
flowchart, see Supplementary Figure A.1). Subjects in the test (n=16) and control (n=17) groups 
(modified ITT population) were comparable with respect to baseline characteristics (Table 1). 
The test group reported 80 medical conditions in the medical history compared to 120 medical 
conditions in the control group. Adherence to the study product, according to diary entries, was 
high (>96%) and equal in both groups.
Safety analysis and concomitant medication
In total 27 adverse events (AEs) were reported, of which no serious AEs. The number of subjects 
with at least one AE did not differ statistically between groups (test: 13 AEs in 8 subjects, control: 
14 AEs in 7 subjects, Fisher’s exact test p=0.732). A total of 15 of 33 subjects (45.5% of the 
total study population) reported at least one AE. AEs that were most often reported for both 
study groups concerned gastro-intestinal system disorders (i.e. abdominal pain, diarrhoea, 
dyspepsia, nausea, vomiting). The majority of AEs were considered to be unrelated to the study 
product. Seven AEs (5 in the test group and 2 in the control group) had a relationship to the 
study product (‘possibly’ or ‘probably’), and were all of gastro-intestinal nature (i.e. diarrhoea, 
dyspepsia, nausea, and vomiting). Regarding the use of concomitant medication (other than 
AD medication), 62.5% of subjects in the test group and 82.4% of the control group used 
Processed on: 23-3-2017
509018-L-bw-Rijpma
Chapter 4
82
Table 1 Subject characteristics
Test
n=16
Control
n=17
Age 74.7 years (4.8) 72.7 years (8.2)
Gender (%) 7 males (44%) 7 males (41%)
MMSE 23.0 (2.1) 23.2 (1.8)
Time since diagnosis 1.7 months [0.4-15.3] 1.4 months [0.2-10.2]
BMI 24.2 kg/m2 (3.8) 26.7 kg/m2 (3.3)
Educational level (%)
   - Low
   - Medium
   - High
6 (37.5%)
8 (50.0%)
2 (12.5%)
4 (23.5%)
9 (52.9%)
4 (23.5%)
Study product compliance 96.4% (4.8) 99.0% (1.6)
MMSE, mini mental state examination; AD, Alzheimer’s disease; BMI, body mass index. Data are presented 
as mean (standard deviation) or median [range] unless otherwise indicated.
concomitant medication until the four weeks intervention period. After the intervention period, 4 
of 16 subjects in the test group and 8 of 17 subjects in the control group started AD medication 
(galantamine, memantine, or rivastigmine). 
Nutritional blood markers
Levels of uridine, choline, and vitamin E in plasma, and percentages of DHA, EPA, and total 
long-chain polyunsaturated fatty acids (LCPUFAs) in plasma as well as in total fatty acids in 
erythrocyte membrane were higher at week 4 in the test group compared with the control group 
(all p<0.001). Homocysteine levels were lower after 4 weeks of test product compared with the 
control product (p=0.006). Docosapentaenoic acid in plasma or erythrocyte membrane was not 
significantly different at week 4 between the groups (p=0.628 and p=0.840, respectively). For 
details see Table A.2.
MRS outcomes 
Good quality 31P and 1H-MR spectra were obtained from all ROIs (Figure 1B and 1D). If no 
significant interactions between intervention group and brain region were observed in the 
statistical analyses, only main intervention group effects are reported. Furthermore, the results 
from the covariate analyses are only reported if the potential confounders substantially changed 
the intervention effect. As the ITT and PP analyses yielded the same findings, only the ITT 
analyses are reported.
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Primary 31P-MRS outcomes 
A significant intervention effect, showing higher PME/PDE at week 4 in the test group than in 
the control group, was found using the main model with observed baseline ( Least Square (LS) 
mean±SEM test: 1.35±0.06, control: 1.17±0.06, p=0.005), but not using the main model with 
imputed baseline (p=0.295) (Table 2). Influential diagnostics revealed an influential subject that 
severely affected the results of the model. Excluding this subject from the  model, resulted in 
a similar effect of the intervention on PME/PDE at week 4 to the model with observed baseline 
(LS mean±SEM test: 1.29±0.06; control: 1.16±0.05, p=0.061, Table 2 Model A). Results from 
the supportive models aligned with the main modeling approach using observed baseline (for 
details, see Table 2, Model B-C). The supportive model D resulted in a significant intervention 
group by time interaction, which expresses the intervention effect (for details, see Table 2, Model 
D). No differences between groups were observed regarding the levels of PME (all models 
p>0.05, e.g. main model - with imputation LS mean±SEM at week 4, test: 12.04±0.19; control: 
11.99±0.19, p=0.845) or regarding levels of PDE (all models p>0.05, e.g. main model - with 
imputation LS mean±SEM at week 4, test: 9.94±0.35; control: 10.41±0.35, p=0.329).
Other 31P MRS outcomes 
The ratio PEth/GPEth  was higher in the test group than in the control group (only main model 
- observed baseline, LS mean±SEM test: 2.02±0.09; control: 1.80±0.09, p=0.091) (Table 3). 
There were no significant differences between groups regarding the ratio PCh/GPCh,  levels of 
PEth, PCh, GPEth, GPCh, PCr, Pi, ATP, or nicotinamide adenine dinucleotide, or pH (all p>0.05). 
1H-MRS outcomes 
Using the main model with observed baseline, a significant interaction with brain region was found 
for tCho/tCr, leading to analyses per brain region. These showed that tCho/tCr at week 4 was 
higher in the test group than in the control group in the ACC (LS mean±SEM test: 0.302±0.015; 
control: 0.258±0.016, p=0.068) and in the HR (LS mean±SEM test: 0.287±0.004; control: 
0.264±0.004, p=0.003), but not in the HL and PCC (both p>0.05) (Table 4). Using the main 
model with imputed baseline, an overall significant intervention effect was found on relative tCho 
levels indicating that tCho/tCr at week 4 was higher in the test group than in the control group 
(Table 4; LS mean±SEM test: 0.264±0.004; control: 0.252±0.004, p=0.019).
In the supportive model of tCho/tCr, the p-value of the three-way interaction between intervention, 
brain region and time was below the pre-specified threshold (p<0.10), leading to per brain region 
analyses. The intervention had no significant interaction with time at any of the brain regions (all 
p>0.05). For absolute levels of tCho, both main models yielded a significant intervention effect 
indicating that levels of tCho were higher at week 4 in the test group than in the control group (LS 
mean±SEM test: 1.95±0.05 and 1.94±0.05; control: 1.84±0.05 and 1.83±0.05, p=0.007 and 
p=0.018; main model with imputed baseline and observed baseline, respectively)
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Figure 2 
LS means±SEM of PME/PDE at week 4 in the test and control group from the main model - observed baseline. 
LS, least square; SEM, standard error of the mean; PME, phosphomonoesters; PDE, phosphodiesters. * = 
p<0.05.
There were no significant differences between groups regarding relative (i.e. relative to tCr) or 
absolute (i.e. water-referenced) levels of NAA or mI, on the ratio NAA/mI or regarding absolute 
levels of tCre, in any of the modeling approaches (all p>0.05).
Discussion
This study investigated whether the medical food Souvenaid, containing nutritional precursors 
and cofactors for phospholipid membrane formation (i.e. FC), influenced brain phospholipid 
metabolism in mild AD. The observed effects indicate that this specific multi-nutrient combination 
not only raises circulating levels of phospholipid precursors after 4 weeks, but also affects the 
balance between brain metabolites of phospholipid formation and breakdown in patients with 
mild AD. In addition, levels of tCho were higher after the intervention in comparison with the 
control product, whereas metabolic measures of neural integrity, gliosis, and energy metabolism 
were not significantly affected. 
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There is strong ex vivo evidence that brain phospholipid content is decreased3, phospholipid 
membrane composition is altered3,26 and phospholipid anabolic and catabolic processes are 
disturbed7,27 in AD and a tight link of these changes with synaptic loss and synaptic dysfunction 
is presumed26,28. The dependence of the unsaturated, low-affinity enzymes in the phospholipid 
synthesis pathway on substrate availability offers the opportunity to support this process by 
Table 2 Results from statistical analysis for PME/PDE; ITT population.
N Test / 
N Control
Mean estimated 
value at week 4
Mean estimated 
group difference 
at week 4
(95% CI)
p-
value
Test Control
Main modeling approach
Imputed BL 15/16 1.25 1.17 0.08 (-0.07,0.23) 0.295
Observed BL 14/15 1.35 1.17 0.18 (0.06,0.30) 0.005
Supportive models
Model A 14/16 1.29 1.16 0.14 (-0.01,0.28) 0.061
Model B 15/16 1.40 1.27 0.13 (-0.03,0.30) 0.105
Model C 14/15 1.44 1.27 0.17 (0.02,0.33) 0.030
Model D 16/17 0.07* -0.09* 0.16 (0.02,0.31)† 0.024#
Model A: Excluding influential subject, imputed BL; Model B: Most complete brain region (i.e. retrosplenial 
cortex), imputed BL; Model C: Most complete brain region (i.e. retrosplenial cortex), observed BL; Model D: 
Time included in model. Forest plots reflect mean estimated group differences at week 4 with 95% CI. PME, 
phosphomonoesters; PDE, phosphodiesters; ITT, intention to treat; CI, confidence interval; BL, baseline; na, 
not applicable. *Mean estimated change from baseline, †mean estimated group difference in change from 
baseline,#p-value for interaction between intervention and time (in days).
Table 3 Results from statistical analysis for PEth/GPEth; ITT population.
N Test / 
N Control
Mean estimated 
value at week 4
Mean estimated 
group difference 
at week 4  
(95% CI)
p- 
value
Test Control
Main modeling approach
Imputed BL 15/16 1.99 1.80 0.18 (-0.06,0.43) 0.135
Observed BL 15/15 2.02 1.80 0.22 (-0.04,0.48) 0.091
Forest plots reflect mean estimated group differences at week 4 with 95% CI. PEth, phosphoethanolamine; 
GPEth, glycerophosphoethanolamine; ITT, intention to treat; BL, baseline; CI, confidence interval.
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Table 4 Results from statistical analysis for tCho; ITT population.
N Test / 
N Control
Mean estimated 
value at week 4
Mean estimated 
group difference 
at week 4 
(95% CI)
p-
value
Test Control
Relative tCho (tCho/tCr)
Main modeling approach
 - Imputed BL 14/16 0.26 0.25 0.01 (0.00,0.02) 0.019
 - Observed BL
   - ACC 10/8 0.30 0.26 0.04 (-0.00,0.09) 0.068
   - PCC1 12/14 0.21 0.20 0.01 (-0.00,0.02) 0.139
   - HL 9/11 0.28 0.28 -0.00 (-0.03,0.03) 0.794
   - HR 9/10 0.29 0.26 0.02 (0.01,0.04) 0.003
Supportive modeling approach
 - Model D
   - ACC 14/11 -0.004* -0.023* 0.019 (-0.047,0.085)† 0.578#
   - PCC 14/16 0.006* -0.004* 0.010 (-0.005,0.024)† 0.197#
   - HL 12/15 -0.015* -0.000* -0.015 (-0.041,0.012)† 0.290#
   - HR 12/14 0.003* 0.005* -0.002 (-0.028,0.023)† 0.869#
Absolute (water-corrected) tCho (mM)
Main modeling approach
 - Imputed BL 14/16 1.95 1.84 0.11 (0.03,0.19) 0.007
 - Observed BL 14/16 1.94 1.83 0.11 (0.02,0.20) 0.018
Model D: Time included in model; 1Supportive model: most complete brain region (posterior cingulate cor-
tex), observed BL. Forest plots reflect mean estimated group differences at week 4 with 95% CI. ITT, intention 
to treat; CI, confidence interval; BL, baseline; na, not applicable. *Mean estimated change from baseline, 
†mean estimated group difference in change from baseline, #p-value for interaction between intervention 
and time (in days).
providing those substrates that are rate limiting. Short-term supplementation with this specific 
multi-nutrient combination increases plasma and erythrocyte levels of nutritional precursors 
and cofactors for phospholipid membrane formation in patients with mild AD, which confirms 
and extends previous studies29, and thus may alleviate pre-existing nutritional deficiencies14. 
As several mechanisms have been described that move key nutrients across the blood brain 
barrier9, the nutrients in the current investigation, or their metabolites, are expected to reach the 
brain. Accordingly, we observed a significantly increased ratio PME/PDE, which is considered 
to reflect the ratio of phospholipid anabolites over catabolites23,30, across four brain regions with 
4 weeks daily use of this multi-nutrient combination in mild AD. This indicates that the nutrients 
exert their effect on the brain’s phospholipid metabolism, in line with the hypothesized mode of 
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action of this multi-nutrient combination. The observed changes in phospholipid metabolism 
may promote neuronal membrane formation, and may stimulate dendritic spine formation, as 
was shown previously in animal studies8,9,11.  This may underlie the effects this intervention has 
on memory in patients with mild AD19,20.
As the ratio PME/PDE changed significantly, but individual and total phosphomonoesters (PEth, 
PCh, and PME) and phosphodiesters (GPEth, GPCh, and PDE) did not, it cannot be established 
whether phospholipid formation was increased, breakdown was decreased, or both. In addition, 
the literature is inconclusive on in vivo levels of these metabolites in AD, since both increased, 
decreased and unaltered levels of PME and PDE have been observed in comparison with 
cognitively normal controls31-36. However, the effect of this multi-nutrient combination on brain 
phospholipid metabolism appears to be mainly driven by the ethanolamine pathway, as PEth/
GPEth, but not PCh/GPCh, showed a trend towards an increase. This is in line with other studies 
that show that oral phospholipid precursors (pyrimidines and choline) in healthy populations37-39 
predominantly affect the ethanolamine pathway. However, in the current study, both relative and 
absolute tCho levels were higher at follow up in the group receiving the multi-nutrient intervention 
than in the control group, indicating an effect on phosphocholine metabolism as well. The tCho 
signal reflects the choline-containing compounds PCh, GPCh and free choline, and while both 
PCh and GPCh were measured separately with 31P-MRS, no increase was detected in either one. 
This discrepancy may have arisen because 1H and 31P-MRS brain volumes were slightly different, 
but supportive statistical models could not confirm the significant alterations of tCho after 4 weeks 
intervention, warranting cautious interpretation. The analyses did reveal that changes in tCho may 
not be anatomically uniform, as most prominent effects were observed in the ACC and HR.  
Reduced levels of NAA and increased levels of mI have been consistently shown in AD40 and it 
might have been expected that this multi-nutrient combination would decelerate the changes in 
these measures of neural integrity and gliosis. Although uridine and DHA were found to stimulate 
neurite outgrowth41,42, and DHA is known to have anti-inflammatory effects in addition to their 
role in the phospholipid synthesis pathway43, no group differences after 4 weeks of intervention 
were observed regarding relative or absolute levels of NAA or mI, nor regarding the ratio NAA/mI. 
However, the normal rate of change over 4 weeks time may be limited, such that a deceleration 
effect of the intervention is not yet discernible, or it may be that the damage that these metabolites 
reflect is already irreversible at this stage of the disease.  
The findings of this study may be limited by the modest sample size. Although there was 
sufficient power to detect an effect on the ratio PME/PDE, one of the main outcome measures, 
it was not possible to ascribe the increase in this ratio to increased PME or decreased PDE. 
Moreover, MR spectra were not always available or of sufficient quality from all investigated brain 
regions. Finally, a longer intervention duration may have led to more robust findings and more 
pronounced secondary outcomes.
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This exploratory double-blind randomized controlled study showed that the medical food 
Souvenaid affects phospholipid metabolism across multiple brain regions in mild AD after only 
4 weeks. This could lead to increased neuronal membrane formation, which would support the 
hypothesized mode of action of this multi-nutrient intervention. Larger and longer randomized 
controlled trials are needed to determine long term effects on phospholipid formation, synaptic 
function and cognition in persons with and at risk for AD. 
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SuPPLEMEnTARy MATERIAL 
Methods 
Subjects and design
Diagnosis of probable or possible AD was made according to the revised National Institute of 
Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related 
Disorders Association (NINCDS-ADRDA) 2011 criteria1 with evidence of the pathophysiological 
process (i.e. from structural MRI or cerebrospinal fluid biomarker assays). A Geriatric Depression 
Scale (GDS) score below 6 (out of 15) was required for inclusion. All subjects were AD drug-
naïve (cholinesterase inhibitors and/or NMDA-antagonists) and were free from neurological or 
psychiatric disorders (other than dementia). To increase subject recruitment, eligibility criteria 
were extended during the study to include patients that were off AD medication for at least three 
months prior to the study, but no additional subjects were recruited that did not comply with the 
original criteria. Consumption of oily fish, more than twice a week, or of nutritional supplements 
containing docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA) was prohibited within two 
months prior to baseline. One month prior to baseline supplements containing more than 200% 
of the recommended daily allowance of vitamins B6 (2.8 mg), B12 (5 ug), C (160 mg), E (24 mg) 
or folic acid (0.4 mg) were prohibited, as well as anticholinergic and antipsychotic medication, 
and other medical foods or investigational products. Additionally, absence or stable doses of 
lipid lowering medications, antihypertensives and antidepressants in the month prior to baseline 
were required. 
Medical history, medication and nutritional supplement use, Mini Mental State Examination, 
GDS, date of birth, sex, ethnicity, smoking habits, alcohol consumption, and family history of AD 
were recorded from all subjects at the first (screening) visit. Level of education was classified 
according to Verhage2 (comparable with the International Standard Classification of Education3) 
and categorized in three groups: primary education or lower (low), junior vocational training 
(middle), and senior vocational or academic training (high).
In the randomization procedure two sets (one for women, one for men) of numbered and sealed 
randomization envelops were generated at Nutricia Research by the Clinical Studies Supplies 
Manager and opened upon randomization on-site by the investigator. Each envelop contained 
one of four codes, half representing the test group and half the control group. All subjects and 
any person involved in subject recruitment, group allocation, data acquisition and processing, 
or statistical analyses were blinded to the intervention group (test or control) until the analyses of 
the main outcome parameters were completed (see 2.4 for details on semi-blinded analyses). 
The composition of the test product is specified in supplementary Table A.1. The study product 
was packaged in tetra-packs (until 15 January 2014) or plastic bottles (from 15 January 2014 
onwards) and labeled with one of the four randomization codes. With assistance from their 
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informal caregiver, subjects recorded  intake of the product daily in a diary, which was used to 
verify intake at the week-4 visit.
 
 Subjects were instructed to minimize intake of high-choline food on the days of the baseline and 
week 4 visits and to keep intake of concomitant nutritional supplements and medication stable 
(unless deemed necessary by their physician) during the study.  
Table A.1 Nutritional composition of the study products; amount per daily dose (125 mL)
Control Active
Energy 125 kcal 125 kcal
Protein 3.8 g 3.8 g
Carbohydrate 16.5 g 16.5 g
Fat 4.9 g 4.9 g
EPA 0 300 mg
DHA 0 1200 mg
Phospholipids 0 106 mg
Choline 0 400 mg
UMP 0 625 mg
Vitamin E (alpha-TE) 0 40 mg
Vitamin C 0 80 mg
Selenium 0 60 µg
Vitamin B12 0 3 µg
Vitamin B6 0 1 mg
Folic acid 0 400 µg
EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; UMP, uridine monophosphate; TE, tocopherol 
equivalents * Test product is Souvenaid, containing the specific nutrient combination Fortasyn Connect. 
Souvenaid and Fortasyn are registered trademarks of Nutricia N.V. 
Biochemical analyses of blood samples 
Analyses of the blood samples were performed as reported previously4. A brief description is 
given here. The fatty acid composition of the total lipid fraction in plasma and erythrocytes was 
analyzed qualitatively on a gas chromatograph after extraction of the lipids from the plasma 
and/or erythrocytes and a methylation step. Plasma vitamin E levels were measured using 
high-performance liquid chromatography (HPLC) to determine the content of alphatocopherol. 
Homocysteine levels (free and protein-bound) were measured using HPLC with fluorescence 
detection after preparing a derivate. To determine plasma uridine level, perchloric acid was 
added to the sample. Uridine was extracted by vortexing the solution, followed by separation 
from other nucleotides and/or nucleosides using reversed-phase HPLC. The compounds 
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were quantified by measuring absorbance compared with a standard. HPLC electrochemical 
detection of plasma-free choline was performed according to a method adapted from Fossati 
et al.5.
MR protocol
High resolution structural MR images were acquired with a T1-weighted magnetisation-prepared 
rapid gradient-echo  sequence (TR=2300 ms, TE=3.16 ms, TI=1100 ms, 15° flip angle, 176 
sagittal slices, slice-matrix size=256×256, slice thickness=1 mm, voxel-size=1×1×1mm, 
TA=6:25 min).
31P-MR spectra were acquired with whole brain 3D MRSI (TR=2000 ms, 40° flip angle, acquisition 
delay=0.10 ms, WALTZ4 proton decoupling at 50% of 512 ms acquisition duration, FOV 
260x260x260 mm; matrix size=10x10x10, acquisition time 13:08 min). K-space was sampled 
with a weighted elliptical phase encoding scheme with four averages. The field of view was 
centered on the midline and parallel to the line from the anterior commissure to the posterior 
commissure. Spatial post-processing consisted of zerofilling to a matrix size of 16x16x16 
followed by spatial Fourier transformation. The nominal volume of the measured voxels is about 
17.5 cc, the effective voxel at 64% of the spatial response function has a spherical shape with a 
volume of about 40 cc6. 
1H-MR spectra of the hippocampus were acquired with a single slice 2D semi Localization by 
Adiabatic Selective Refocusing (sLASER) MRSI sequence, with water suppression enhanced 
through T1 effects (WET) (TR=2100 ms, TE=30 ms, 90° excitation flip angle, NA=6, nominal 
voxel size=3.75x5x10mm), positioned parallel to the hippocampi.  1H-MR spectra of the anterior 
and posterior cingulate cortex (ACC and PCC) were acquired with a single voxel point resolved 
spectroscopy (PRESS) sequence with chemical shift selective water suppression (CHESS) 
(TR=3000 ms, TE=30 ms, 90° excitation flip angle, NA=64, voxel size=27x15x15 mm (ACC) 
and 20x20x16 mm (PCC)). With each sequence an additional MR spectrum without water 
suppression was obtained (2D SLASER: NA=1, PRESS: NA=8). The complete MR protocol, 
including positioning of the patient, took approximately 90 minutes. As the 31P-MRS outcomes 
PME, PDE and PME/PDE were the main outcome measures, 31P-MRS measurements were 
always performed before 1H-MRS measurements, in case subjects failed to complete the entire 
scanning protocol.
31P-MRS data analysis
Using the T1-weighted images the MRSI grid was shifted in the x, y and z dimension to position 
voxels in the ROI’s. For the ACC, a voxel was selected anterior to the genu of the corpus callosum, 
with the inferior border aligned with the the line from the anterior commissure to the posterior 
commissure (AC-PC line), and on the midsagittal plane. For the retrosplenial cortex (RSC), a 
voxel on the midsagittal plane was selected posterior to the splenium of the corpus callosum, 
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with the inferior border aligned with the AC-PC line. For left and right hippocampus (HL and HR), 
a voxel was selected at the anterior end of each hippocampus, with the inferior and lateral border 
of the voxel aligned with the inferior and lateral side of the hippocampus. 
The software package Metabolite Report (Siemens Healthcare, Erlangen, Germany) was 
used for post-processing (i.e. zero-filling, phase correction,100 ms exponential filter, baseline 
correction) and for automatic fitting of the spectra in the time-domain using prior knowledge 
appropriate for 31P MR spectra (own data and de Graaf7). Eleven well-resolved resonance peaks 
were fitted: the phospholipid metabolites phosphoethanolamine (PEth), phosphocholine (PCh), 
glycerophosphoethanolamine (GPEth) and glycerophosphocholine (GPCh), the high-energy 
phosphorus molecules phosphocreatine (PCr), adenosine triphosphates (ATP), α-ATP, β-ATP and 
γ-ATP, nicotinamide adenine dinucleotide (NAD(H)) and inorganic phosphate (Pi), and membrane-
bound phospholipid (MP). Regarding the quantitative evaluation of the fitting results, only metabolite 
fits with a Cramer–Rao lower bound (CRLB) of ≤30% were considered reliable. Qualitatively, two 
spectroscopists (AR and MvdG) independently checked the spectra by visual inspection of the 
original spectra and the fitting results. If a metabolite peak was visually present, and its fit was 
assigned to the correct resonance—giving a minimal residue—the fitting result was accepted. 
Since the intensity of each metabolite resonance was expressed as a percent area of the total 
phosphorous signal area., our data are corrected for CSF content and thus for differences in 
atrophy. Intracellular pH was determined from the chemical shift difference between the PCr and 
Pi resonance peaks8. 
1H-MRS data analysis
The software package LCModel (Version 6.3-0C9) was used for post-processing (e.g. eddy 
current correction and water scaling) and for automatic fitting of all 1H-MR spectra (i.e. 2 
hippocampal voxels, ACC and PCC). Regarding the quantitative evaluation of the fitting results, 
a whole spectrum was rejected when the full-width-half-maximum >0.15 ppm (18.5 Hz) or the 
signal-to-noise ratio (S/N) <5, and only individual metabolite fits with a CRLB below 30% were 
considered reliable. Qualitatively, two spectroscopists (AR and MvdG) independently judged 
the original spectra and the fitting results by visual inspection according to a pre-specified set 
of criteria. 
MRI data analyses
T1-weighted MR images from one visit were segmented into grey matter (GM), white matter (WM) 
and cerebrospinal fluid (CSF) using automatic segmentation software (SPM8, Welcome Trust 
Centre for Neuroimaging, London, UK; VBM8, Structural Brain Mapping Group, Jena, USA).  For 
each subject the whole brain GM fraction (GM / (GM + WM + CSF)) was calculated and used 
as a pre-specified confounder in supportive covariate analyses (see section 2.7).
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Figure A.1 
Flowchart of subjects in study. ITT, intention to treat; PP, per protocol.  
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Table A.2 Intervention effect on nutritional blood markers and homocysteine. 
Blood outcome parameter Mean estimated 
value at week 4
Difference 
between 
groups at 
week 4
p-value for 
intervention 
effect
Test
n=16
Control
n=17
Fatty acids in the erythrocyte membrane
DHA (%) 4.9 2.8 2.1(1.84,2.30)        <0.001
EPA (%) 1.7 0.8 0.8(0.69,0.98) <0.001
DPA (%) 1.6 1.6 0.014(-0.12,0.15) 0.840
LC-PUFA (=DHA+EPA+DPA) (%) 8.2 5.3 2.9(2.51,3.24) <0.001
Fatty acids in blood plasma
DHA (%) 4.4 1.5 2.9(2.59,3.12) <0.001
EPA (%) 2.1 0.8 1.3(1.10,1.51) <0.001
DPA (%) 0.50 0.49 0.008(-0.03,0.04) 0.628
LC-PUFA (=DHA+EPA+DPA) (%) 7.0 2.8 4.2(3.79,4.53) <0.001
Choline levels in blood plasma (uM) 14.4 9.0 5.4(3.39,7.47) <0.001
Vitamin E levels in blood plasma (uM) 50.9 39.6 11.4(6.77,15.96) <0.001
Homocysteine  levels in blood plasma (uM) 9.8 12.4 -2.6(-4.31,-0.82) 0.006
Uridine levels in blood plasma (uM) 14.8 2.6 12.2(7.24,17.11) <0.001
95% confidence interval (CI) is presented between brackets; DHA, docosahexaenoic acid; EPA, 
eicosapentaenoic acid; DPA; docosapentaenoic acid; LC-PUFA, long-chain polyunsaturated fatty acids.
Processed on: 23-3-2017
509018-L-bw-Rijpma
Chapter 4
98
References
1. McKhann, G.M., et al., The diagnosis of dementia due to Alzheimer's disease: recommendations from the 
National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's 
disease. Alzheimer's & Dementia, 2011. 7(3): p. 263-9.
2. Verhage, F., Intelligentie en leeftijd: onderzoek bij Nederlanders van twaalf tot zevenenzeventig jaar. 
1964: Van Gorcum.
3. United Nations Educational Scientific and Cultural Organization, International Standard Classification of 
Education ISCED 2011. 2012, Institute for Statistics: Montreal, Canada.
4. Rijpma, A., et al., Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and 
mild-to-moderate Alzheimer's disease. Alzheimer's Research & Therapy, 2015. 7(1): p. 51.
5. Fossati, T., et al., Determination of plasma choline by high-performance liquid chromatography with a 
postcolumn enzyme reactor and electrochemical detection. Journal of Chromatography. B, Biomedical 
Applications, 1994. 656(1): p. 59-64.
6. Pohmann, R. and M. von Kienlin, Accurate phosphorus metabolite images of the human heart by 3D 
acquisition-weighted CSI. Magnetic Resonance in Medicine, 2001. 45(5): p. 817-826.
7. de Graaf, R., In vivo NMR spectroscopy. Principles and techniques. Second Edition ed. 2008, Chichester 
John Wiley.
8. Petroff, O.A.C., et al., Cerebral intracellular pH by 31P nuclear magnetic resonance spectroscopy. 
Neurology, 1985. 35(6): p. 781.
9. Provencher, S.W., Estimation of metabolite concentrations from localized in vivo proton NMR spectra. 
Magnetic Resonance in Medicine, 1993. 30(6): p. 672-679.
Processed on: 23-3-2017
509018-L-bw-Rijpma
Souvenaid affectS brain phoSpholipid metaboliSm in mild alzheimer’S diSeaSe
99
4
Processed on: 23-3-2017
509018-L-bw-Rijpma
Processed on: 23-3-2017
509018-L-bw-Rijpma
Published as: A. Rijpma, O. Meulenbroek, M.G.M. Olde Rikkert, 2014. 
Cholinesterase inhibitors and add-on nutritional supplements in Alzheimer’s disease: 
A systematic review of randomized controlled trials. Review Article. 
Ageing Research Reviews, 16, 105-112.
5
 Cholinesterase inhibitors and add-on nutritional 
supplements in Alzheimer’s disease. A systematic 
review of randomized controlled trials
Processed on: 23-3-2017
509018-L-bw-Rijpma
Chapter 5
102
Abstract
To date, single drug and nutrient-based interventions have failed to show a clinically relevant 
effect on Alzheimer’s disease (AD). Multidomain interventions may alleviate symptoms and 
alter the disease course in a synergistic manner. This systematic review examines the effect 
of adding nutritional supplementation to cholinesterase inhibitors.  A systematic PubMed and 
Cochrane search resulted in nine high quality studies. The studies had low to moderate risk of 
bias and focused on oxidative stress, homocysteine levels, membrane fluidity, inflammation and 
acetylcholine levels. Only the use of vitamin E supplements could reduce the rate of functional 
decline when combined with cholinesterase inhibitors in one study, whereas cognition was 
not affected in both this and other studies. None of the other nutritional supplements showed 
convincing evidence of a beneficial effect when combined with cholinesterase inhibitors. This 
shows that cognitive and functional improvement is difficult to achieve in patients with AD, 
despite epidemiological data and evidence of biological effects of nutritional supplements. 
Addressing one disease pathway in addition to cholinesterase inhibitor therapy is probably 
insufficient to alter the course of the disease.  Personalized, multifactorial interventions may be 
more successful in improving cognition and daily functioning. 
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Introduction
There is wide interest in the role nutrition plays in the development and disease process of 
neurodegenerative diseases. Epidemiological evidence suggests that certain diet patterns or 
dietary elements can prevent or slow the development of Alzheimer’s disease (AD)1. In particular, 
low intake of omega-3 fatty acids, antioxidants and B-vitamins, have been associated with an 
increased risk of AD2. Moreover, brain structure and cognitive performance have been shown 
to be positively influenced by dietary nutrients, such as B-vitamins3,4. These findings raise the 
question whether supplementation with nutritional components may be of benefit to patients with 
Alzheimer’s disease. 
There are several disease pathways and risk factors in AD that could theoretically be affected 
by nutritional factors, such as oxidative stress, high homocysteine levels, reduced membrane 
fluidity, inflammation and low acetylcholine levels5-9. 
A proposed mechanism of oxidative stress is that activation of protein kinases, enhancing beta- 
and gamma-secretase activity, and lipid DNA and protein oxidation are induced by reactive 
oxygen species (ROS), leading to neuronal cell death10,11. The increased neurofibrillary tangle 
and amyloid-beta load in turn increase the amount of ROS. High homocysteine levels may lead 
to neurodegeneration by amyloid-beta peptide generation, hyperphosphorylation of tau or direct 
neurotoxic effects, or through its role in cerebrovascular pathology reviewed in 12. Reduced 
membrane fluidity may lead to impaired neuronal communication, since that is dependent on 
proper functioning of membrane related  mechanisms such as postsynaptic receptor functioning, 
and presynaptic fusion and endocytosis of vesicles13. Neuroinflammation, albeit most likely a 
secondary event, can cause or exacerbate neuronal death and is most prominent in those brain 
areas with high levels of AD pathology7. Finally, loss of cholinergic neurons in de nucleus basalis 
lead to actylcholine deficiencies and contribute to impaired memory in patients with AD8. 
Previous reviews have focused on nutrient status in patients with AD14 or on the effect of single 
nutrients, such as vitamin E15, or nutrient groups, such as B-vitamins16 on cognition. To date, single 
nutrients have failed to show an indisputable, clinically significant effect on the severity or course 
of the disease, despite consistent epidemiological evidence of protective effects. This may be 
due to the heterogeneity of AD, which may be based on the multi-causal nature of the disease, 
thus suggesting that a multidimensional intervention is necessary to reach an improvement in 
cognition or daily function17,18. Treatments in which multiple elements are combined may have 
the potential to create a synergistic effect on the disease process, and interest in combination 
treatment has grown over the years. Therefore, this systematic review examines the effect of 
nutritional supplements combined with cholinesterase inhibitors on cognition and functional 
performances in patients with Alzheimer’s disease. 
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Methods
This review has been reported according to guidelines of the Dutch Cochrane Centre19 and 
meta-analyses (PRISMA) guidelines for reporting systematic reviews20.
A comprehensive search strategy was developed to identify intervention trials which assessed 
the impact of cholinesterase inhibitors with nutritional supplements on Alzheimer’s disease using 
both medical subject headings (MeSH) and key word terms. A complete listing of search terms 
is provided in the appendices (A, PubMed; and B, Cochrane Library). A preliminary search was 
performed in PubMed on January 16, 2012 and in the Cochrane Library on January 24, 2012; 
no language or date restrictions were applied in the search. However, studies in a language 
other than English were later excluded. E-mail notifications identifying  new studies matching the 
search terms in PubMed were evaluated  (AR) for eligible studies until May 17, 2013.  Reference 
lists of all eligible studies were further cross-checked to identify additional trials.  
Eligible studies included randomized controlled trials (RCTs) in which: 
1)  patients with Alzheimer’s disease were included, (based on internationally accepted criteria); 
2)  the intervention consisted of one or more nutritional supplements;
3)  the subjects where either given cholinesterase inhibitors  as part of the intervention or were 
stable on cholinesterase inhibitors at the start of the study;
4) the population was aged 50 years or older.
Studies conducted in patients with major physical or cognitive disabilities (other than AD) and 
other types of dementia (e.g. Parkinson’s disease dementia, Lewy Body dementia, vascular 
dementia) were excluded, as they were beyond the scope of this review. Studies in a language 
other than English were also excluded. 
Risk of bias for the selected studies was independently assessed by two reviewers (OM and AR) 
using form II for RCT from the Evidence Based Guideline Development (EBRO; workgroup on 
guideline development, including the Dutch Cochrane Centre). After consensus was reached 
a judgment of low risk (+), unclear risk (?) or high risk (-) of bias was made on six types of 
bias: 1) ‘Allocation’ refers to the random allocation to treatment groups; 2) ‘blinding´ refers to 
the degree of blinding that was applied (e.g. of participants or investigators); 3) ‘incomplete 
outcome data’ refers to loss to follow up; 4) ‘selective reporting’ refers to not reporting on all 
outcome measures; 5) ‘comparable treatment groups’ refers to whether there were any relevant 
differences between the treatment groups (e.g. age or age at onset of AD); 6) ‘other bias’ refers 
to other sources that could increase the risk of bias, such as carry-over effects in cross-over 
designs or conflicts of interest. Data on study and participant characteristics, supplement dose, 
method of cognitive assessment, and relevant outcomes were independently extracted by two 
reviewers (OM and AR). Where necessary, the corresponding author of the study was contacted 
to provide additional information. 
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Results
The electronic search to January 2012 resulted in a total of 479 results. After the removal of 32 
duplicate citation, the 447 remaining citations were assessed for eligibility (Figure 1). Based on 
the title and/or abstract, 413 records were excluded, leaving 31 citations for which the fulltext 
articles were obtained. An additional six records were identified by cross-checking the reference 
lists from the 31 potentially eligible studies. Of these six records, four were immediately excluded 
based on the abstract. Thus, 33 full article citations were reviewed for eligibility. Following 
assessment by two authors (AR and OM), six articles describing five unique studies were 
included.
E-mail notification from PubMed up to April 8, 2014 resulted in the inclusion of four additional 
studies, resulting in a total of nine individual studies included in the final version of this review. 
Risk of bias
The nine included studies had low to moderate risk of bias, as is shown in Figure 2. Random 
allocation and blinding of the patients and investigators to treatment group were well performed 
across most studies. However, the open-label study of Arlt et al.21, was vulnerable to bias due 
to the randomization method and lack of blinding. The occurrence of incomplete outcome data 
could not be excluded in three out of nine studies22-24. Selective reporting could not be determined 
for all but one study24; little information was available on the placebo used and whether the 
reported outcome measures were the only ones used. For five out of nine studies, the treatment 
groups were comparable23,25-28. One study had a high risk of bias on this item, since treatments 
groups were not comparable with respect to age and age of onset of the disease21 and the risk 
was unclear for two studies since no characteristics of subgroups were reported24 or differences 
between groups were not formally tested22. There was generally low risk of other forms of bias, 
the only potential bias comes from Shah et al.29  which was funded and co-authored by industry 
and Freund-Levi et al.26, which was co-funded by industry.  
Effect of nutritional supplements
The study characteristics and results of all nine studies are summarized in table 1. In case 
additional interventions were described that did not meet our inclusion criteria, we only evaluated 
and extracted the data that were relevant to the current study (e.g. the comparison between 
memantine and vitamin E22 was not evaluated in this paper). Below the results of the studies are 
discussed grouped by nutritional compound and pathophysiological pathway connected to the 
supplements. 
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Figure 1 
Flowchart of search process in PubMed and Cochrane library databases  
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Figure 2 
Summary of bias of the included studies; + low risk, - high risk, ? unclear risk.
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Oxidative stress
Three studies21,22,28 examined the added effect of antioxidants to cholinesterase inhibitor therapy. 
Arlt et al.21 found that vitamin C and E in addition to donepezil had a slightly negative effect on 
cognition (MMSE score decreased compared to baseline in the vitamin group). Cornelli et al.28 
found that Formula F had no or minimal effect on cognition (more cases improved on MMSE 
II score in treatment arm compared to placebo arm). Dysken et al.22 found no effect of vitamin 
E in addition to a cholinesterase inhibitor on cognition but did show a reduction in the rate of 
functional decline over a mean follow-up of 2.27 years. The other two studies did not assess 
functional outcome. Taking into account the low to moderate risk of bias, there is little evidence 
of a benefit of anti-oxidants in combination with cholinesterase therapy on cognition. There is, 
however, support for decreased rate of functional decline in mild to moderate male patients with 
AD taking vitamin E in addition to cholinesterase inhibitors.
Acetylcholine precursors 
Two studies23,24 reported the added effect of acetylcholine precursors to cholinesterase therapy. 
As found by Amenta et al.24, choline alphoscerate in addition to donepezil had a modest positive 
effect on cognition and function, relative to the intervention group, the placebo group showed 
a decline in cognition after 12 months follow-up. In contrast,  Foster et al.23 found no effect of 
lecithin in addition to tacrine on cognition and function. With a moderate risk of bias for Amenta 
et al.24 and a low risk of bias for Foster et al.23, the data do not suggest a positive effect of 
acetylcholine precursors in combination with cholinesterase inhibitors on cognition or function.
Increased homocysteine levels
Four studies25,27-29 reported nutritional interventions that are related to reducing high 
homocysteine levels. Connelly et al.27 reported a modest positive effect of folic acid in addition to 
a cholinesterase inhibitor on cognition and a modest positive effect on functional outcome. The 
number of ‘responders’ according to NICE criteria was higher in the intervention group receiving 
both a cholinesterase inhibitor and folic acid in contrast to the comparison group which only 
received a cholinesterase inhibitor. A significant difference in change from baseline in combined 
Instrumental Activities of Daily Living and Social Behaviour score was observed between the 
groups. Two studies25,29 observed no differences in cognition or function between treatment 
with only conventional AD medication (cholinesterase inhibitor with or without memantine) and 
the combined treatment with AD medication and B vitamin (B6, B12 and folic acid) containing 
supplements . Cornelli et al.28 found that Formula F, containing among other nutrients vitamin 
B6, B12 and folic acid, had a slight effect on cognition (more cases improved on MMSE II score 
in treatment arm compared to placebo arm). This study did not assess functional outcome. All 
studies had a low risk of bias. Thus, whereas a positive effect of folic acid in combination with 
cholinesterase inhibitors on cognition and function was observed in the study by Connelly et al, 
such was not the case, or only minimal, for the other studies, which investigated the combination 
of folic acid with other B vitamins and additional nutrients. 
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Membrane fluidity and inflammation
Two studies reported on effects of omega-3 fatty acids26,31 or omega-3 fatty acids containing 
supplements29 in conjunction with cholinesterase inhibitor therapy. In both studies, the addition 
of omega-3 fatty acids (DHA and EPA) to a cholinesterase inhibitor had no effect on function 
and minimal or no effect on cognition compared to treatment with only a cholinesterase inhibitor. 
Modest improvements were only observed by Freund-Levi et al.26 in very mild cases of AD. Given 
the low risk of bias of both studies the current evidence does not support a positive effect of 
omega-3 fatty acids in combination with cholinesterase inhibitors on cognition or function.
Discussion
In this review, we found little evidence that adding antioxidants, acetylcholine precursors, 
B-vitamins or omega-3 fatty acids to cholinesterase inhibitor therapy has a positive effect on 
cognition or activities of daily life in patients with Alzheimer’s disease. The use of vitamin E 
supplements could reduce the rate of functional decline when combined with cholinesterase 
inhibitors in only one study, whereas cognition was not affected in both this and other studies. 
Interestingly, although beyond the scope of this review, the beneficial effect of vitamin E was 
diminished by adding memantine. Regarding B-vitamins one study observed a beneficial effect 
with folic acid27,  whereas other RCTs comprised of patients with more advanced AD found that 
adding B-vitamins including folic acid to a cholinesterase inhibitor had no effect on cognition or 
function25,29.  Recent systematic reviews focusing on single nutrients or nutrient groups only, have 
also failed to find an effect on cognition in cognitively impaired and/or unimpaired people16,32,33. 
The diversity of nutritional supplements investigated in the included studies is large, which 
exemplifies the quest for nutritional intervention but impedes direct comparisons. However, the 
heterogeneity between studies allows for the opportunity to examine multiple disease pathways 
and compare studies, grouped by their disease modifying factors. The heterogeneity of the 
included studies provides a broad overview of the topic, and therefore, our conclusions are not 
limited to one domain.
Although the evidence did not support the effect of nutritional supplements on cognition or 
function, several studies did find a positive effect on intermediate outcomes, suggesting effects 
on the underlying mechanism they were trying to influence21,25,28. For instance, Arlt et al.21 found 
oxidation of cerebral spinal fluid (CSF) lipids to be reduced after one year of supplementation 
with the antioxidants  vitamin C and E, while the clinical course of AD over one year was not 
affected. 
There are three possible explanations for the absence of an effect on cognition and function, in the 
presence of a biological effect. Firstly, administration of supplements may be too late for patients 
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who have already developed overt AD. In these patients, although the underlying causative 
mechanism can be positively influenced, the damage that has been caused in the brain resulted 
in cognitive impairment, and is thus too large to be restored. Trials in patients with (very) mild 
cognitive impairment, or at high risk to develop cognitive decline, would help clarify this issue, 
provided that the follow-up time is sufficient to monitor progression to dementia. Unfortunately 
this is often not the case, as in Lee et al.34, who reported improvement in cognition in MCI patients 
after 12 months DHA treatment but provided no data on conversion to AD. In such cases, a 3 year 
follow-up period would likely be required to adequately assess disease progression. However, 
Petersen et al.35 could not identify an effect of 3 year treatment with vitamin E on progression to 
AD. Thus, intervention may be necessary even before the onset of mild cognitive problems. Trials 
in large numbers of cognitively healthy people over long periods of time may however not be 
feasible, unless they contain an enriched population with multiple risk factors.
Second, even more than two disease-modifying mechanisms may have to be addressed, in 
order to alter cognition and functional outcome. Multi-nutrient formulas have been developed 
for this purpose, such as formula FTM  and SouvenaidTM (both included in this review). These 
have yielded mixed results and some controversy in literature but there may be larger positive 
effects, restricted to mild AD cases28,36,37. Combining physical and cognitive training with 
nutritional interventions have been explored as well, again with mixed results38,39. Altogether, the 
available research has not yet provided convincing evidence that combining multiple treatments 
is more beneficial in AD than a single treatment. More research is needed on which nutritional 
supplements and other treatments should be combined, as well as on which study designs are 
most appropriate for this. Currently, quality indicators have been developed for studies reporting 
on combined interventions, underlying the specific methodological issues in such complex 
interventions40,41. Ideally studies investigating the combined use of two treatments apply a 
factorial design, sufficiently powered to detect the interaction effects, and mostly including four 
groups: a true control group without intervention, two groups  receiving either treatment alone 
and a group receiving both treatments. This can of course be extended to multiple combinations. 
In addition, an optimal treatment duration and follow-up time is required to monitor the difference 
in disease progression. A scientifically sound example is the factorial design used by Dysken et 
al.22, where a follow-up of up to 4 years allowed for modeling the rate of decline. Future studies 
that take above recommendations into account can advance our knowledge and move the field 
to a higher level.
Last, multiple trajectories may result in Alzheimer’s disease, making the disease not only 
multifactorial but adding to phenotypical heterogeneity as well. Different modifiable factors may 
underlie disease progression in different patients, and therefore personalized interventions may 
be necessary to address these specific needs. For instance, in one patient high homocysteine 
levels and inflammation may be more prominent, while for another patient oxidative stress 
and decreased membrane fluidity may be key factors. Some studies provide evidence for this 
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paradigm. For instance, Lloret and colleagues42 investigated vitamin E supplements and oxidative 
stress in patients with AD. For those patients in whom vitamin E supplementation led to lower 
oxidative stress (lower blood oxidized glutathione levels), cognitive function was maintained. 
In contrast, among patients whose oxidative stress was not reduced by treatment with vitamin 
E, an accelerated cognitive decline was observed. This supports the idea that personalized 
medicine can lead to better treatment effects, especially in Alzheimer’s disease which may be 
multifactorial in etiology and has proven to be heterogenic in its presentation18,43.
Limitations
Because unpublished and grey literature (informally published written material) were not included 
in this review, publication bias may have affected the presented results. However, a funnel plot 
analysis could not be performed due to insufficient amount of data and the heterogeneity between 
outcome measures. Several studies with negative results were identified nonetheless, implying 
minimal publication bias. Since this review was restricted to English language publication, 
potentially eligible studies in other languages may have been excluded from this review. 
Conclusion
In this review multiple nutritional interventions in addition to cholinesterase inhibitor therapy were 
examined. Only the use of vitamin E supplements could reduce the rate of functional decline 
when combined with cholinesterase inhibitors in one study, whereas cognition was not affected 
in both this and other studies. None of the other nutritional supplements showed convincing 
evidence of a significant effect on cognition or daily functioning. However, cognitive and functional 
improvement is difficult to achieve in patients with AD, despite epidemiological evidence and 
biological effects of nutritional supplements. This is most likely due to the multifactorial nature 
of AD, apart from effects of right timing of the interventions, and appropriate trial design and 
duration. Thus, addressing one pathway in addition to cholinesterase inhibitor therapy is likely 
insufficient to influence symptoms, let alone alter the course of the disease. A personalized and 
multifactorial intervention may potentially have a greater impact on symptoms and clinical signs 
from the earliest course of the disease onwards. A more personalized approach to treatment in 
early AD should be investigated as only this treatment type is tailored to the individual patient’s 
(multidomain) deficiencies and disease mechanisms. In combination with early diagnosis and 
intervention , personalized medicine will be necessary to combat Alzheimer’s disease. 
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Appendix A
Pubmed search strategy:
Search strategy:    created by LL
Date search:  16-01-2012
Limits:   None 
Hits:   367 
Initial selection:  by LL and OM 
Search strategy:
1. "Dementia"[Mesh]
2. dementia*[tiab]
3. “cognitive impairment”[tiab]
4. “cognitive function”[tiab]
5. “cognitive performance”[tiab]
6. “cognitive decline”[tiab]
7. “cognitive loss”[tiab]
8. “cognitive dysfunction”[tiab]
9. "cognition disorders"[MeSH Terms]
10. "cognition disorders"[tiab]
11. “cognitive disorders”[tiab]
12. "alzheimer disease"[MeSH Terms]
13. alzheimer*[tiab]
14. "mild cognitive impairment"[tiab]
15. MCI[tiab]
16. "Dementia, Vascular"[Mesh]
17. "vascular dementia"[tiab]
18. OR/1-17
19. "factorial design"[tiab]
20. factorial[tiab]
21. "Randomized Controlled Trials as 
Topic"[Mesh]
22. "Randomized Controlled Trial"[Publication 
Type]
23. "random allocation"[Mesh]
24. "double blind method"[Mesh]
25. RCT[tiab]
26. "clinical trial"[tiab]
27. random*[tiab]
28. controlled[tiab]
29."double blind"[tiab]
30. "single blind"[tiab]
31. "multidomain intervention"[tiab]
32. "multidisciplinary intervention"[tiab]
33. "multicomponent intervention"[tiab]
34. OR/19-33
35. interaction*[tiab]
36. “complex intervention*” [tiab]
37. “combination therapy"[tiab]
38. "combination treatment"[tiab]
39. multicomponent[tiab]
40. "Exercise"[Mesh]
41. "Movement"[Mesh:noexp]
42. "Physical therapy modalities"[Mesh]
43. "Life Style"[Mesh:noexp]
44. exercise[tiab]
45. "physical exercise"[tiab]
46. "life style"[tiab]
47. lifestyle[tiab]
48. training*[tiab]
49. “dementia medication”[tiab] 
50. medication[tiab]
51. "Cholinesterase Inhibitors"[Mesh]
52. “cholinesterase inhibitor”[tiab]
53. “nmda receptor antagonist”[tiab]
54. “nmda antagonist”[tiab]
55. galantamine[tiab]
56. rivastigmine[tiab]
57. donepezil[tiab]
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58. memantine[tiab]
59. OR/35-58
60. "Dietary Supplements"[Mesh:noexp]
61. nutrition therapy[Mesh]
62. nutritional support[Mesh]
63. “nutritional support”[tiab]
64. nutrition*[tiab]
65. neutraceutical*[tiab]
66. nutraceutical*[tiab]
67. diet*[tiab]
68. food[tiab]
69. “caloric restriction”[tiab]
70. nutrient[tiab]
71. supplement*[tiab]
72. "nutritional supplementation"[tiab]
73. "nutrition therapy"[tiab]
74. "dietary supplement"[tiab]
75. homocystein[tiab]
76. antioxidant*[tiab]
77 vitamin*[tiab]
78. "omega 3"[tiab]
79. "folic acid"[tiab]
80. pyridoxine[tiab]
81. cobalamin[tiab]
82. "ascorbic acid"[tiab]
83. tocopherol[tiab]
84. selenium[tiab]
85. “β-carotene”[tiab]
86. PUFA[tiab]
87. "omega 3"[tiab] 
88. "n-3"[tiab] 
89. "omega 6"[tiab] 
90. "n-6"[tiab]
91. DHA[tiab]
92. “docosahexaenoic acid”[tiab]
93. EPA[tiab]
94. “eicosapentaenoic acid”[tiab]
95. UMP[tiab]
96. "linolenic acid"[tiab] 
97. "linoleic acid"[tiab] 
98. ALA[tiab] 
99. LA[tiab] 
100. "arachidonic acid"[tiab]
101. choline[tiab]
102. phospholipid*[tiab]
103. phosphatidylcholine"[tiab]
104. "lecithin"[tiab] 
105. "phosphatidylserine"[tiab]
106. “uridine-5'-monophosphate”[tiab]
107. “uridine monophosphate”[tiab]
108. OR/60-107
109. animal*[tiab]
110. mice[tiab]
111. OR/109-110
112. 18 AND 34 AND 59 AND 108 NOT 111
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Appendix B 
The Cochrane Library search strategy:
Search strategy:    created by LL
Date search:  24-01-2012
Limits:   None 
Hits (Trials):  112 
Initial selection:  by LL and OM 
Search strategy:
dementia 
cognitive impairment
1 OR 2 
vitamin
antioxidant
nutrition
4 OR 5 OR 6 
3 AND 7 
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Key findings
•  Circulating levels of nutrients, relevant for the phospholipid synthesis pathway and 
known to be decreased in the AD population, can be increased within weeks in 
patients with mild AD by a multi-nutrient intervention. 
•  Uptake of nutrients reaches a plateau phase for most nutrients during prolonged in-
take, thus increasing the availability of precursors and cofactors in the circulation that 
may be used for the formation and function of neuronal membranes and synapses 
in the brain.
•  Increased levels of phosphocreatine in regions that show early degeneration and an 
increased tissue pH suggest that brain energy metabolism is altered in mild AD.
•  Although preclinical and post-mortem studies have shown alterations in membrane 
function and lipid composition in AD, no alterations in phospholipid metabolism were 
found in vivo in mild AD.  
•  Short term multi-nutrient supplementation affects brain phospholipid metabolism in 
patients with mild AD.
•  Short term multi-nutrient supplementation does not alter neural integrity in patients 
with mild AD.
•  The addition of vitamin E to cholinesterase inhibitor therapy in AD may slow functional 
decline. 
•  The addition of nutritional supplements to cholinesterase inhibitor therapy in AD does 
not reduce cognitive decline.
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AD is a progressive neurodegenerative disease affecting more than 20 million people worldwide 
and is the leading cause of dementia in older persons. Memory loss, and problems with planning, 
language and wayfinding are among its devastating effects. Despite immense research efforts, 
a cure for AD is not available. Several lifestyle factors have been identified that can reduce or 
increase the risk for dementia or AD, such as diet. This has raised much interest in the role 
nutrition plays in AD, and whether nutrients or nutritional supplements can affect the course 
and the pathology of this disease. One of the pathological pathways that may be amenable to 
nutritional intervention, is the brain’s phospholipid metabolic pathway. Any drug or nutritional 
intervention aiming to prevent, reduce, or reverse cognitive symptoms in AD must find its way to 
the circulation and onwards to the brain in order to affect clinical outcome. The research in this 
thesis explores the effects of nutrients in AD, with a focus on those nutrients that are involved in 
phospholipid metabolism, at several levels of this route. 
In chapter 2 we investigated the first step in the route from nutrient intake to cognitive effects. 
Data from three RCTs representing more than 900 people with mild to moderate AD and including 
both drug-naïve patients as well as patients on AD medication were analyzed. We showed that 
a multi-nutrient intervention can increase plasma and/or erythrocyte micronutrient levels (uridine, 
choline, selenium, folate, DHA, EPA, and vitamins B6, B12 and E) after 12-24 weeks. Uptake of 
most nutrients was observed already after 6 weeks and reached a plateau between 24 and 48 
weeks of daily intake. Analyses on a subset of mild AD patients revealed no effects of this multi-
nutrient combination on markers of inflammation or oxidative stress. To conclude, circulating 
levels of micronutrients can be reliably increased in a diverse AD population by a multi-nutrient 
intervention. This forms the basis for any effects these nutrients can have on phospholipid 
metabolism, neuronal membrane formation, and ultimately synaptic function and cognition. 
In the next chapter we examined brain phospholipid and energy metabolism in vivo, using state-
of-the-art techniques, in a large group of patients with AD and healthy older adults. Contrary 
to our expectations, and despite various reports of post mortem phospholipid membrane 
alterations, we did not observe any differences in phospholipid metabolism in patients with 
mild AD compared to their age-matched controls. However, we did see alterations in energy 
metabolism in AD. Most interestingly, phosphocreatine, an important energy molecule, was 
increased in those regions that show early degeneration in AD, but not in a region that is involved 
at a later stage. 
Although phospholipid metabolite levels were not different from normal, we showed in 
chapter 4 in a double-blind RCT that it is possible to influence brain phospholipid metabolism 
through a multi-nutrient intervention. After 4 weeks, the ratio of phospholipid precursors (i.e. 
phosphomonoesters) to phospholipid breakdown products (i.e. phosphodiesters) was 
significantly increased in mild AD patients that received this investigational product once daily 
compared to patients that received a control product. This shows that the nutrients, or their 
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metabolites, cross the blood brain barrier and affect the metabolic pathway for which they are 
substrates. However, measures of neural integrity were unaffected by this intervention. 
Finally, in chapter 5 we turned to other multi-domain interventions and their effect on cognition 
and daily function. Specifically, in a systematic review we looked at single and multi-nutrient 
supplements as an addition to cholinesterase inhibitor therapy. Only for vitamin E some evidence 
was found to support that addition to cholinesterase inhibitor therapy may slow functional decline. 
However, cognitive decline was not affected by addition of vitamin E nor any other nutritional 
supplement. This shows that cognitive and functional improvement is difficult to achieve in 
patients with AD, despite epidemiological evidence of risk reduction and biological evidence of 
the effects of nutritional supplements. 
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31P-MRSI uncovered anatomical pattern of energy abnormality in AD
In this thesis we describe the largest study to date that investigated key molecules of energy 
and phospholipid metabolism in AD by 31P-MRS (chapter 3). Recent advances in this technique 
allowed us to perform whole brain measurements in under 15 minutes. This enabled us to 
assess high-energy phosphates, phospholipid metabolites and pH in four brain regions of 
interest in AD simultaneously. At the start of this study we expected to mainly find differences 
between AD patients and healthy controls in phospholipid metabolites.  However, we did not 
observe any differences in phospholipid metabolism. Instead, a novel finding emerged from 
this investigation. We found for the first time increases in PCr, PCr/Pi and pH in mild AD patients 
compared to age- and gender-matched controls, indicating an altered energy metabolism in AD. 
In order to understand the relevance of this finding, we need to briefly explore energy metabolism 
in the brain. 
High-energy phosphates play a central role in energy metabolism in cells, forming the currency 
of energy production and utilization1. ATP is necessary for all cellular processes that require 
energy, whether it is the maintenance of the membrane potential or neurotransmitter release from 
a presynaptic site. PCr functions as a temporal and spatial energy buffer to quickly replenish ATP 
when energy demands suddenly or locally increase in tissues with a high and fluctuating energy 
consumption. It also functions as a buffer to enhance the efficiency of mitochondrial oxidative 
phosphorylation by keeping ADP levels available in sufficient amounts. In the brain, two isoforms 
of the enzyme creatine kinase (CK) are present, cytosolic brain type CK (BCK) and ubiquitous 
mitochondrial CK (uMtCK), that convert PCr, ADP and one proton (H+) to ATP and creatine, or 
vice versa. Usually, ATP is then immediately utilized to release its energy potential, and ADP and 
Pi are generated. In muscle this is clearly seen when upon exercise PCr concentrations drop 
and Pi levels rise, with ATP levels remaining stable. In brain tissue, the situation is more complex 
as the brain is always active and fluctuations in energy demand are more local and likely faster. 
In the study described in chapter 3 of this thesis we looked at steady state levels of PCr, ATP 
and Pi and at intracellular pH in AD and normal aging. Because we acquired whole brain data, 
we could determine that the increase in PCr in patients with AD was not uniform across the 
four investigated brain regions. Increased levels were found in the RSC and both hippocampi, 
regions that are known to be involved early on in the disease, whereas levels in the ACC, a region 
affected later in the course of AD, were unaltered. This resembles the anatomical pattern seen 
in tau pathology, glucose hypometabolism and atrophy. We can now add these new findings 
to the biomarker graph from the introduction in Figure 1. The in vivo alterations we found in our 
research in mild AD patients corroborate post-mortem findings of impaired CK enzyme activity 
and indicate that changes in energy metabolism are not just present in end-stage disease. 
Together with the distinct anatomical pattern of PCr abnormalities, this suggest that these 
processes may be important in the pathophysiology of AD. 
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Figure 1 
Hypothetical graph of appearance of imaging biomarker abnormalities in different brain regions, updated 
from Figure 1 in the introduction. Top panel, Anatomical variation exists in the time courses of biomarker 
abnormalities within imaging modes (FDG-PET and structural MRI). Bottom panel, similarly to FDG-PET and 
structural MRI, one would expect abnormalities in phosphocreatine to appear in the following order based 
on the current results: medial temporal lobe, retrosplenial cortex/posterior cingulate,  anterior cingulate. Top 
panel reprinted with permission from Jack et al. (2010)2.
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In future research, the first step would be a whole brain analysis (of the current dataset) to expand 
our description of the anatomical pattern of PCr increase. In addition, magnetization transfer 
experiments to determine the CK and ATPase reaction rates would extend the current steady-
state findings. Finally, the investigation of at-risk populations as well as correlation of energy 
metabolites with other pathologies or with cognitive performance would be particularly interesting 
to determine the time course and significance of these alterations in energy metabolism. 
Phospholipid metabolism alterations may be a late stage process in AD 
One of the most surprising findings from the work in this thesis, or actually lack of a finding, is the 
absence of differences in phospholipid metabolites between patients with AD and healthy aged 
controls. This raises the question whether phospholipid metabolism and phospholipid content 
of neuronal membrane are pathologically relevant to AD. Previous studies that used post-
mortem brain tissue showed that the brain's major phospholipids PE and PC were decreased 
in AD in several regions3. Additionally, phospholipid catabolic enzyme activity is decreased and 
activity of phospholipid re-synthesis enzymes is increased compared to controls4. Furthermore, 
ex vivo biochemical analyses have detected that the DHA content of neuronal membrane was 
decreased5,6, thereby influencing membrane fluidity. This is expected to have a direct influence 
on cell signaling pathways because membrane fluidity affects synaptic vesicle release, receptor 
recycling and second messenger signaling7,8. This is all compelling evidence that phospholipid 
metabolism and phospholipid membrane composition is altered in AD. So why did we not 
observe any differences in vivo between AD patients and healthy aged controls in our study? 
The conclusion may have to be that phospholipid metabolism is not yet affected at this stage. 
Any post mortem analysis is most likely from end-stage AD, while the patients in our study 
were recently diagnosed, and classified as mild AD. Although we must consider the possibility 
that our measurements lacked the sensitivity or specificity to detect differences in the levels of 
MRS observable phospholipid metabolites, this is not very plausible as we could demonstrate 
changes in these metabolites after a short nutritional intervention. Thus, most likely, abnormalities 
in phospholipid metabolism take place at the later stages of AD.   
To further examine the time course of phospholipid alterations in AD, it would be necessary to 
repeat these measurements at several stages of the disease. A longitudinal study would be 
preferable, but a cohort study with pre-clinical, mild and severe AD patients could be a first step. 
This would allow the detection of changes in metabolite levels over the course of the disease. 
We should be aware though that changes in biomarkers over time are often not linear and that 
the precise pattern may only be discovered using longitudinal studies. 
Brain phospholipid metabolism can be influenced by a short term multi-
nutrient intervention
If we are still confident that phospholipid metabolism is pathologically relevant to AD, does it 
make sense to support phospholipid formation before deficits develop? Actually, this is exactly 
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the direction in which the field is heading. Early intervention is likely of essence, should we have 
any change of fighting neurodegenerative diseases9. 
In chapters 2 and 4, we demonstrated that plasma and erythrocyte levels of nutrients, that have a 
role in the phospholipid synthesis pathway, can be reliably increased after only 4 weeks in patients 
with mild AD and that most levels reach a plateau phase after sustained intake between 24 and 
48 weeks. Moreover, in chapter 4 we showed that short term daily supplementation with these 
same nutrients increases the ratio of phosphomonoesters to phosphodiesters. Thus, the balance 
between building blocks and breakdown products of phospholipids is altered, which indicates 
that intake of these nutrients affects phospholipid metabolism. As neither phosphomonoester 
signals nor phosphodiester signals were significantly changed after 4 weeks, we were unable to 
determine whether this is due to increased phospholipid formation or to decreased phospholipid 
breakdown. Our results did indicate that the increase is driven by changes in the ethanolamine-
containing phospholipids and that the effect on choline-containing phospholipids is smaller 
or absent. This is not to say that brain choline levels cannot be increased, as the total level 
of choline-containing compounds (mainly choline-containing phospholipids and free choline) 
was higher after 4 weeks of the intervention compared with intake of a control product. A slight 
difference in 1H and 31P-MRS brain volumes could be underlying this discrepancy between the 
results on choline-containing phospholipids from the different MRS measurements. 
Besides their effect on the phospholipid synthesis pathway, we also expected this multi-nutrient 
intervention to slow down changes in brain metabolites related to neural integrity and gliosis. 
For instance, DHA has anti-inflammatory effects10 (which may be relevant for gliosis) and both 
uridine and DHA can influence neurite outgrowth11,12 (which could result in improved neuronal 
health). However, this short term intervention did not affect brain levels of NAA, a marker for 
neural integrity, levels of mI, a marker for gliosis, or the ratio NAA/mI. Possibly, the normal rate of 
change of these metabolites over 4 weeks time is limited, such that a deceleration effect of the 
intervention is not yet discernible, or it may be that the damage that these metabolites reflect is 
already irreversible at this stage of the disease.  
Our results show that we can influence those processes that are not yet affected in mild stage 
AD (i.e. phospholipid metabolism), but not those that are already disturbed at this stage (neural 
integrity and gliosis). This suggests that a higher gain may be expected with earlier intervention, 
when pathology is less advanced. The field has been moving towards earlier interventions in 
recent years9 and several trials are underway that even try to prevent cognitive decline in those 
genetically predisposed to develop AD13,14. The multi-nutrient intervention that was the focus of 
this research, is investigated in an ongoing trial in a group of individuals at risk for developing 
AD (i.e. having mild cognitive impairments [MCI]), with the aim to reduce or prevent cognitive 
decline. Those results will shed more light on whether earlier intervention is indeed associated 
with a higher gain, and whether intervention at this MCI-stage is early enough.     
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Nutritional interventions in AD: too little, too late, and too general 
Although the majority of the research in this thesis concerns the biology of AD and the 
biological effects of nutrients, in chapter 5 we turned our attention to the clinical endpoints in 
AD. In a systematic review, we investigated what happens with cognition and daily function 
when a nutritional supplement is added to cholinesterase inhibitors, one of the two drugs with 
proven, albeit modest and temporary, efficacy in AD. This yielded rather disappointing results, 
as no supplement could improve cognition or slow cognitive decline and only slim evidence 
was provided for improved daily function with the addition of vitamin E. Despite mounting 
epidemiological evidence on the role of nutrition in cognition and dementia15,16, interventions 
with nutritional supplements repeatedly fail to show an effect on cognition. This is not only the 
case for people that already have AD17-19, but also in cognitively healthy (elderly) populations 
the prevention of cognitive decline or dementia is difficult to achieve20. Interestingly, many 
interventions do show biological effects on the pathways they aim to influence. For instance, 
B-vitamins do lower homocysteine levels in hyperhomocysteinemic cognitively intact older 
persons but do not improve cognitive performance21, and anti-oxidant supplements reduce 
markers of oxidative stress in cerebrospinal fluid (CSF) in AD patients, but without clinical 
efficacy22. This biological efficacy without clinical benefit alludes to three facts that may influence 
the current lack of successful trials to reduce or prevent cognitive decline. Firstly, interventions 
may be initiated too late. The commonly held view nowadays is that neurodegenerative diseases 
like AD start decades before the onset of symptoms9. Even in the aged population, pathological 
processes may be too advanced for interventions to be able to counteract or repair the damage 
that causes cognitive decline. Secondly, a multifactorial disease like AD may require simultaneous 
intervention on multiple domains. Multiple causes of AD may have to be addressed in order to 
improve clinical outcome. A recent trial showed modest success when diet, vascular health, 
and social health were all addressed together in a population of community-dwelling elderly23. 
Finally, AD is a highly heterogenic disease. Therefore, clinical effects of interventions may be lost 
on a group level when the dominant biological pathways that contribute to cognitive impairment 
are different for each individual. A recent trial aimed at reducing cardiovascular risk factors in 
community-dwelling older persons failed to reduce the incidence of dementia and cardiovascular 
disease after 6 years24. This lack of efficacy may be partly ascribed to a high standard of usual 
care, but one could also speculate that the intervention effect was diluted by individuals in which 
cardiovascular health did not contribute to cognitive impairment. To tackle all three issues, we 
should aim for early multi-domain interventions that are tailored to the individual patient.  
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Clinical implications and future perspectives 
Personalized medicine in nutritional interventions
As discussed above, the pathway to AD may be different for each individual. In each individual 
a different combination of several pathological processes leads to cognitive impairment. This 
is illustrated in Figure 2, where hypothetical graphs are shown for three different individuals. In 
patient 1, fi ve factors equally contribute to his impairment. The cognitive impairment of patient 
2 is much more dominated by amyloid beta and tau pathologies. In a third patient, oxidative 
stress and membrane dysfunction are the dominant pathologies. One can imagine that reducing 
ROS by anti-oxidants does not do much for patient 2, while it may be of benefi t to patient 3. But 
the largest effi cacy may be expected in patient 3, when both oxidative stress and membrane 
dysfunction are addressed. Of course, this requires knowledge of the pathways that are relevant 
at an individual level. 
Figure 2 
Hypothetical graphs of the contribution of pathological pathways to cognitive dysfunction in different patients.
The current era of personalized medicine places emphasis on tailored healthcare in contrast 
to a ‘one size fi ts all’ approach. The European Alliance for Personalised Medicine defi nes 
personalized medicine as ‘a targeted approach to the prevention, diagnosis and treatment 
of disease based on an individual’s specifi c profi le25. This can also be applied to nutritional 
interventions as they can be tailored to different underlying pathological mechanisms and to 
individual defi ciencies and heightened needs. However, many factors besides the effi cacy of 
such interventions infl uence their prospects. Time and costs of diagnostic tools, costs of making 
individually tailored supplements or personalized diet advice, lack of user convenience, and lack 
of resources may be obstacles for implementation. Notwithstanding, the anticipated gain is a 
great motivator to tackle the obstacles we may be faced with, increasing the odds for successful 
implementation. 
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31P-MRS based biomarkers 
In our research we used state-of-the-art MR spectroscopic techniques that uncovered 
abnormalities in energy metabolism in early stage AD with a distinct anatomical pattern. We 
speculate that this anatomical pattern reflects sequential involvement of brain areas, as has 
been shown for other pathologies in AD (Figure 1). At the same time, our results suggest that 
abnormalities in phospholipid metabolism may become relevant only at a late stage in the 
disease. In Figure 3 we have added our findings to the hypothetical model of AD biomarkers 
and their relationship with clinical disease stage9. Next to the current neuroimaging techniques 
PET, fMRI and volumetric MRI, that provide knowledge on amyloid beta accumulation, synaptic 
dysfunction and brain structure, we can now add 31P-MRSI that gives us information on energy 
and phospholipid metabolism. The question comes to mind what role 31P -MRSI could have in 
monitoring disease progression and whether 31P -MRS based biomarkers would be feasible. 
Figure 3 
Hypothetical model of dynamic biomarkers. Aβ as identified by cerebrospinal fluid Aβ42 assay or positron 
emission tomography (PET) amyloid imaging. Synaptic dysfunction evidenced by fluorodeoxyglucose PET 
(FDG-PET) or functional magnetic resonance imaging (fMRI), with a dashed line to indicate that synaptic 
dysfunction may be detectable in carriers of the 3/4 allele of the apolipoprotein E gene before detectable 
Aβ deposition. Neuronal injury is evidenced by cerebrospinal fluid tau or phospho-tau, brain structure 
is evidenced by structural MRI. Energy and phospholipid metabolism abnormalities are evidenced by 
phosphorus MR spectroscopy (31P-MRS). Biomarkers change from normal to maximally abnormal (y-axis) 
as a function of disease stage (x-axis). The temporal trajectory of two key indicators used to stage the 
disease clinically, cognitive and behavioral measures, and clinical function are also illustrated. Adapted with 
permission from Sperling et al. (2011)9.
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It is certain that this technique adds a unique insight in disease processes that cannot be 
measured in vivo in any other way. Moreover, like conventional MRI, it is non-invasive and low 
risk compared to FDG-PET and CSF measures, making it especially suitable for repeated 
measurements. However, there are also barriers for implementation. Compared to proton MRI, 
phosphorus has a low intrinsic signal intensity, hindering measurements at a high resolution 
within a (clinically) feasible timeframe. In turn, low resolution increases partial volume effects 
that will contribute to between-subject variability. Practically, current clinical implementation of 
31P-MRS is hindered by the fact that most clinical MR systems are not normally equipped for 
nuclei other than proton (i.e. X-nuclei, such as 31P). However, in light of upcoming developments 
in clinical MR, great progress is expected from 7 tesla MR systems26, which will allow for 31P 
-MRSI at a higher spatial resolution. Additionally, with the current findings of PCr abnormalities 
with anatomical variation in AD, it would be particularly interesting to explore the feasibility and 
relevance of PCr imaging. Since PCr is the dominant peak in the cerebral 31P-MR spectrum, 
measurement time can be reduced if the purpose would only be to reliably measure PCr, 
compared to when an entire spectrum needs to be (reliably) obtained. Hereby, whole brain 
PCr imaging with a reasonable resolution and within a clinically acceptable timeframe becomes 
attainable. If PCr abnormalities prove to be specific for AD, these measurements would bring the 
use of PCr as a biomarker of AD within reach.
Concluding remarks
The research in this thesis explored the effects of nutrients in AD, with a focus on those nutrients 
that are involved in phospholipid metabolism. We demonstrated that both circulating levels as 
well as essential brain metabolic processes can be influenced by a multi-nutrient supplementation 
that contains precursors and cofactors for the synthesis of membrane phospholipids. Ultimately, 
this may reduce cognitive decline by supporting synapse function. However, at the moment, 
there is no evidence that the addition of nutritional supplements to standard AD medication 
reduces cognitive decline in mild AD patients. The current research also led to the discovery 
of abnormalities in high-energy phosphate metabolism in mild AD with a distinct anatomical 
pattern. With future technical advances in (phosphorus) MR, phosphocreatine may become a 
novel MR-based biomarker of AD.    
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nEDERLAnDSE SAMEnvATTIng 
Inleiding
De ziekte van Alzheimer is  de meest voorkomende oorzaak van dementie bij ouderen. 
Wereldwijd zijn er meer dan 20 miljoen mensen met deze vorm van dementie. Bij de ziekte van 
Alzheimer krijgen mensen problemen met hun geheugen, met het plannen van activiteiten, met 
hun taalgebruik en met het vinden van de weg in hun omgeving. Ondanks de enorme inzet 
van onderzoekers is genezing van de ziekte van Alzheimer onmogelijk. Er wordt daarom veel 
onderzoek gedaan naar leefstijlfactoren, omdat het kansen biedt voor het voorkomen van deze 
ziekte.  Voeding is bijvoorbeeld een leefstijlfactor waarvan we weten dat het de kans op het 
krijgen van de ziekte van Alzheimer, of dementie in het algemeen, kan vergroten of verkleinen. 
Er is veel interesse in de vraag of en hoe voedingsstoffen het beloop of ontstaan van de ziekte 
van Alzheimer kunnen beïnvloeden. Met name de verbindingen tussen hersencellen (synapsen) 
zijn daarbij interessant: hoe goed die verbindingen functioneren is namelijk mogelijk te 
beïnvloeden met voedingsstoffen. Dit komt doordat de bouwstenen van de verbindingen continu 
aangemaakt en afgebroken worden en er dus zo continu een behoefte aan bouwstenen bestaat. 
Het belangrijkste component van de bouwstenen zijn de fosfolipiden en de continue opbouw en 
afbraak daarvan noemen we fosfolipidenmetabolisme. Wij krijgen fosfolipiden binnen door het 
eten van bijvoorbeeld vette vis.    
Of we nu voeding eten of medicijnen innemen: om de cognitieve symptomen van de ziekte van 
Alzheimer te kunnen voorkomen, verminderen of omkeren, moet een interventie zijn weg vinden 
naar de hersenen via de (bloed)circulatie. Alleen dan kan het klinisch beloop veranderd worden. 
In dit proefschrift heb ik onderzocht wat het effect van verschillende voedingsstoffen (nutriënten) 
op de hersenen van mensen met de ziekte van Alzheimer is en of de voedingsstoffen in de 
circulatie terecht komen. Hierbij heb ik me met name gericht op nutriënten die betrokken zijn 
bij het fosfolipidenmetabolisme. De meest gebruikte techniek in dit proefschrift is magnetische 
resonantie spectroscopie (MRS), een techniek waarmee we metabolieten in de hersenen 
kunnen onderzoeken op een niet-invasieve manier, vergelijkbaar met MRI. Zo kunnen we o.a. 
de metabolieten onderzoeken die een rol spelen bij het fosfolipidenmetabolisme. Daarnaast 
krijgen we informatie over het energiemetabolisme. Hieronder volgt een samenvatting van de 
bevindingen. 
Het effect van voedingsstoffen op de (bloed)circulatie en de hersenen.
In hoofdstukken 2 en 4 onderzochten we het effect van een interventie die meerdere nutriënten 
bevat (een multi-nutriënte interventie), bij mensen met de ziekte van Alzheimer. Deze multi-
nutriënte combinatie bevat voedingstoffen die een rol spelen bij de aanmaak en afbraak van 
fosfolipiden. In hoofdstuk 2 analyseerden we de gegevens van meer dan 900 mensen met de 
ziekte van Alzheimer die eerder hadden meegedaan aan drie grote studies naar het effect van 
deze interventie op o.a. het geheugen. Deze patiënten gebruikten 24 tot 48 weken lang elke 
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dag de multi-nutriënte combinatie of een controle product. In het bloed van de patiënten zagen 
we dat de niveaus van de nutriënten die in het geteste product zaten (vitamines, mineralen 
en vetzuren) na 6 weken, 12 weken en 24 weken gestegen waren. Als het product nog langer 
gebruikt werd, dan bleven de niveaus stabiel. In een deel van de patiënten hebben we ook 
gekeken of er een  effect was op ontstekingswaarden in het bloed of tekenen van oxidatieve 
stress, maar dit was niet het geval in deze studie.
Nadat we in hoofdstuk 2 hadden laten zien dat de voedingsstoffen uit het product een effect 
hadden op de bloedwaarden,  gingen we in hoofdstuk 4 een stap verder. We onderzochten of 
er ook een effect was op de hersenen bij mensen met de ziekte van Alzheimer. In deze studie 
hebben we patiënten (in het beginstadium van de ziekte) gevraagd om 4 weken lang elke dag 
de multi-nutriënte combinatie of een controleproduct te gebruiken. Vooraf en na deze periode 
hebben we met MRS het fosfolipidenmetabolisme en de neurale integriteit onderzocht. We 
zagen dat de verhouding tussen de bouwstenen van fosfolipiden en de afbraakproducten van 
fosfolipiden verhoogd was in de hersenen na 4 weken. Daarmee hebben we laten zien dat we in 
korte tijd het fosfolipidenmetabolisme (een essentieel metabool proces) in de hersenen kunnen 
beïnvloeden met een voedingsinterventie. We konden echter niet aantonen dat ook de neurale 
integriteit veranderd was in deze korte tijd.
Fosfolipiden- en energiemetabolisme in de ziekte van Alzheimer
Omdat er onvoldoende informatie was over het fosfolipidenmetabolisme bij mensen met de ziekte 
van Alzheimer, onderzochten we dit in hoofdstuk 3 met behulp van de laatste ontwikkelingen 
op het gebied van (fosfor) MRS. Tegelijkertijd gaven deze metingen ook informatie over het 
energiemetabolisme van de hersenen. Studies van het brein van mensen met de ziekte van 
Alzheimer die waren overleden hadden veranderingen in fosfolipiden laten zien. Wij zagen 
echter geen verschillen in het fosfolipidenmetabolisme tussen patiënten in het beginstadium 
van de ziekte van Alzheimer en een groep van even oude gezonde deelnemers. We zagen wel 
veranderingen in het energiemetabolisme. De interessantste bevinding was dat het belangrijke 
energiemolecuul fosfocreatine verhoogd was. Die verhoging zagen we in die delen van het brein 
die al vroeg zijn aangedaan in de ziekte van Alzheimer, maar niet in een ander deel van het brein 
dat pas later betrokken raakt bij de ziekte. 
Voedingssupplementen als aanvulling op medicatie.
In hoofdstuk 5 bekeken we in een uitgebreid literatuuronderzoek of voedingssupplementen iets 
toevoegen aan de traditionele behandeling met medicatie (choline-esterase remmers zijn  de 
meest gebruikte medicijnen bij de ziekte van Alzheimer). Hierbij keken we dit keer naar effecten 
op cognitief functioneren (o.a. geheugen) en dagelijks functioneren (o.a. zelfstandig kunnen 
wassen, aankleden, eten). We zagen dat de toevoeging van vitamine E-supplementen aan 
choline-esterase remmers van alle onderzochte supplementen als enige de achteruitgang in 
dagelijks functioneren kon vertragen. De cognitieve achteruitgang werd echter niet beïnvloed 
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door de toevoeging van vitamine E of enig ander voedingssupplement. Hoewel we weten dat 
voedingssupplementen het risico op de ziekte van Alzheimer kunnen verkleinen en effect hebben 
op het lichaam en de hersenen, laat deze studie zien dat het erg lastig blijkt om in patiënten met 
de ziekte van Alzheimer te zorgen voor een cognitieve of functionele verbetering. 
Conclusies
Met de studies in dit proefschrift onderzocht ik de effecten van nutriënten in de ziekte van Alzheimer, 
met een focus op die nutriënten die betrokken zijn bij het fosfolipidenmetabolisme. We toonden 
aan dat zowel nutriëntenniveaus in de (bloed)circulatie als essentiële metabole processen in het 
brein beïnvloed kunnen worden door multi-nutriënte supplementatie, die bouwstenen voor de 
aanmaak van fosfolipiden bevat. Uiteindelijk zou dit cognitieve achteruitgang kunnen verminderen 
door de ondersteuning van het functioneren van synapsen. Echter, uit een literatuuroverzicht 
bleek dat er op dit moment geen bewijs is dat de toevoeging van voedingssupplementen 
aan standaard Alzheimer-medicatie de cognitieve achteruitgang van patiënten vertraagt. Het 
huidige onderzoek heeft ook geleid tot de ontdekking van afwijkingen in het energiemetabolisme 
in de ziekte van Alzheimer, waarbij er sprake is van een specifiek anatomisch patroon. Met 
toekomstige technologische vooruitgangen in (fosfor) MR, zou fosfocreatine kunnen uitgroeien 
tot een nieuwe MR-biomarker voor de ziekte van Alzheimer. 
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LIST OF ABBREvIATIOnS
1H   proton 
31P   phosphorus 
A-A   active-active
ACC   anterior cingulate cortex 
AD    Alzheimer's disease
ADAS-cog   Alzheimer's Disease Assessment Scale, cognitive subdomain
ADAS-noncog   Alzheimer's Disease Assessment Scale, non-cognitive subdomain 
ADCS-ADL   Alzheimer's Diseae Cooperative Study Activities of Daily Living 
ADP   adenosine diphosphate
AE   adverse event 
ANCOVA   analysis of covariance
ApoE   apolipoprotein E
ATP   adenosine triphosphate 
BADL    Basic Activities of Daily Living 
BMI    body mass index
C-A    control-active
CAS    Caregiver Activity Survey
CASI   Cognitive Abilities Screening Instrument
CDR   Clinical Dementia Rating scale
CGIC   Clinical Global Impression of Change
ChE-I   cholinesterase inhibitor
CK   creatine kinase
Cr   creatine
CRP   C-reactive protein
CSF   cerebrospinal fluid
DHA   docosahexaenoic acid 
DPA   docosapentaenoic acid 
DSST   Digit Symbol Substitution Test
EPA   eicosapentaenoic acid
FC   Fortasyn Connect
GM   grey matter
GPCh   glycerophosphocholine
GPEth   glycerophosphoethanolamine
Hcy   homocysteine
HL   left hippocampus 
HPLC   high-performance liquid chromatography 
HR   right hippocampus 
IADL   Instrumental  Activities of Daily Living
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IL   interleukin
ITT   intention to treat
LS   least square
MCI   mild cognitive impairment
MDA   malondialdehyde
mI   myo-inositol
MMSE   Mini Mental State Examination
MRS   magnetic resonance spectroscopy
MRSI   magnetic resonance spectroscopic imaging
n-3 LC-PUFA  n-3 long-chain polyunsaturated fatty acids
NAA   N-acetyl aspartate
NAD(H)   nicotinamide adenine dinucleotide
ND   not done
NOSGER  Nurses Observation Scale for Geriatric patients
NS   non-significant
OLE   open-label extension
OXPHOS  oxidative phosphorylation
PC   phosphatidylcholine
PCh   phosphocholine 
PCr   phosphocreatine 
PDE   phosphodiesters 
PE   phosphatidylethanolamine
PET   positron emission tomography
PEth   phosphoethanolamine 
Pi   inorganic phosphate 
PME   phosphomonoesters
RCT   randomized controlled trial
RDA   recommended dietary allowance
ROI   region of interest
RSC   retrosplenial cortex 
SB   Social Behavior
SD   standard deviation 
SEM   standard error of the mean
tCho   total choline
tCr   total creatine
TE   tocopherol equivalents
TMT   Trail Making Test
UK   unknow 
UMP   uridine monophosphate
WM   white matter
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